Amarantus BioScience (AMBS) 10-K6 Apr 152014 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2014	Apr. 03, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	Amarantus Bioscience Holdings, Inc.
Entity Central Index Key	1424812
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AMBS
Entity Common Stock, Shares Outstanding		1,041,953,973
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$74,334,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$214	$1,033
Deferred funding fees, net	0	109
Prepaid expenses and other current assets	198	106
Total current assets	412	1,248
Restricted cash	204	0
Property and equipment, net	145	0
Intangible assets, net	1,497	611
Total assets	2,258	1,859
Current liabilities:
Accounts payable	3,353	972
Accounts payable - Regenicin	2,550	0
Related party liabilities and accrued interest	252	248
Accrued expenses	149	292
Accrued interest	25	112
8% senior convertible debentures, net of discount	0	932
Convertible promissory notes	0	124
Derivative liability	0	5,859
Total current liabilities	6,329	8,539
Total liabilities	6,329	8,539
Commitments and contingencies
Series D convertible preferred stock, $1,000 stated value, 1,300 shares designated; 1,299.327 issued and outstanding as of December 31, 2013	0	839
Stockholders' equity (deficit)
Common stock, $0.001 par value, 2,000,000,000 and 1,000,000 shares authorized as of December 31, 2014 and December 31, 2013, respectively; 842,190,750 and 574,171,945 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively	842	574
Additional paid-in capital	45,050	18,938
Accumulated deficit	-55,183	-27,032
Total stockholders' equity (deficit)	-4,071	-7,519
Total liabilities and stockholders' equity (deficit)	2,258	1,859
Series A Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	0	0
Series B Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	0	0
Series C Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	1	1
Series D Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	1,169	0
Series E Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	$4,050	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Common Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	2,000,000,000	1,000,000
Common Stock, Shares Issued	842,190,750	574,171,945
Common Stock, Shares Outstanding	842,190,750	574,171,945
Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Series A Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock Shares, Designated	250,000	250,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock Shares, Designated	3,000,000	3,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock Shares, Designated	750,000	750,000
Preferred Stock, Shares Issued	750,000	750,000
Preferred Stock, Shares Outstanding	750,000	750,000
Series D Convertible Preferred Stock [Member]
Temporary Equity, Stated Value (in dollars per share)		$1,000
Temporary Equity, Shares Designated		1,300
Temporary Equity, Shares Issued		1,299
Temporary Equity, Shares Outstanding		1,299
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$1,000
Preferred Stock Shares, Designated	1,300
Preferred Stock, Shares Issued	1,299
Preferred Stock, Shares Outstanding	1,299
Preferred Stock, Liquidation Preference, Value	$1,299
Series E Convertible Prefered Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$1,000
Preferred Stock Shares, Designated	6,000
Preferred Stock, Shares Issued	4,500
Preferred Stock, Shares Outstanding	4,500
Preferred Stock, Liquidation Preference, Value	$4,500

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Net sales	$0	$0
Operating expense:
Research and development	13,762	2,089
General and administrative	7,592	3,622
Total operating expense	21,354	5,711
Loss from operations	-21,354	-5,711
Other income (expense):
Interest expense	-813	-2,631
Loss on issuance of common stock	-260	-352
Loss on issuance of debt	0	-6,709
Loss on extinguishment of convertible debt	-1,250	0
Loss on issuance of warrants	-3,867	0
Other expense	-50	0
Change in fair value of warrants and derivative liabilities	317	271
Total other expense	-5,923	-9,421
Net loss	-27,277	-15,132
Preferred stock dividend	875	38
Net loss attributable to common stockholders	($28,152)	($15,170)
Basic and diluted net loss per common share (in dollars per share)	($0.04)	($0.03)
Basic and diluted weighted average common shares outstanding (in shares)	788,933,978	450,931,510

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
In Thousands, except Share data	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balances at Dec. 31, 2012	($3,528)	$0	$343	$7,991	($11,862)
Balances (in shares) at Dec. 31, 2012		250,000	342,516,931
Preferred stock - Series A converted to common	127	0	8	119	0
Preferred stock - Series A converted to common (in shares)		-250,000	8,094,117
Preferred stock - Series C issued to officers as compensation	39	1	0	38	0
Preferred stock - Series C issued to officers as compensation (in shares)		750,000	0
Common stock issued for services	860	0	21	839	0
Common stock issued for services (in shares)		0	21,199,822
Common stock issued to acquire intangible assets	79	0	2	77	0
Common stock issued to acquire intangible assets (in shares)		0	2,000,000
Common stock issued in settlement of accounts payable	260	0	8	252	0
Common stock issued in settlement of accounts payable (in shares)		0	7,430,922
Common stock issued in settlement of notes payable	2,200	0	94	2,106	0
Common stock issued in settlement of notes payable (in shares)		0	93,860,499
Common stock issued upon conversion of convertible promissory notes	1,559	0	98	1,461	0
Common stock issued upon conversion of convertible promissory notes (in shares)		0	98,455,794
Common stock issued for Series D convertible preferred stock dividend	0	0	0	12	-12
Common stock issued for Series D convertible preferred stock dividend (in shares)		0	413,860
Loss on issuance of common stock	352	0	0	352	0
Common stock issued upon exercise of common stock options	0	0	0	0	0
Common stock issued upon exercise of common stock options (in shares)		0	200,000
Debt discount written off - associated with convertible promissory notes	-250	0	0	-250	0
Beneficial conversion feature - debt discount - convertible promissory notes	226		0	226	0
Beneficial conversion feature - Series D Convertible Preferred stock	321		0	321	0
Relative fair value associated with senior secured convertible debentures issued with detachable warrants	1,939		0	1,939	0
Derivative liability reclassified upon conversion of convertible promissory notes	2,712		0	2,712	0
Series D convertible preferred stock 8% dividend accrued at period end	-26		0	0	-26
Stock-based compensation expense	744	0	0	744	0
Net loss	-15,132	0	0	0	-15,132
Balances at Dec. 31, 2013	-7,519	1	574	18,939	-27,032
Balances (in shares) at Dec. 31, 2013		750,000	574,171,945
Common stock issued for services	663	0	8	655	0
Common stock issued for services (in shares)		0	7,645,649
Common stock issued to acquire intangible assets	354	0	6	348	0
Common stock issued to acquire intangible assets (in shares)		0	5,500,000
Common stock issued to acquire in-process research and development	3,000	0	38	2,962	0
Common stock issued in settlement of accounts payable	68	0	1	67	0
Common stock issued in settlement of accounts payable (in shares)		0	803,589
Common stock issued in private placement	3,074	0	30	3,044	0
Common stock issued in private placement ( in shares)		0	30,041,120
Common stock issued in consideration of commitment fees for equity financing	516	0	6	510	0
Common stock issued in consideration of commitment fees for equity financing (in shares)		0	6,468,001
Deferred funding costs charged to equity upon termination of advisory agreement	-190	0	0	-190	0
Common stock issued upon conversion of 8% convertible debentures, including accrued interest	8,423	0	86	8,337	0
Common stock issued upon conversion of 8% convertible debentures, including accrued interest (in shares)		0	86,473,409
Common stock issued for Series D convertible preferred stock dividend	0	0	3	100	-103
Common stock issued for Series D convertible preferred stock dividend (in shares)		0	3,464,872
Loss on issuance of common stock	260	0	0	260	0
Common stock issued upon exercise of common stock warrants	4,975	0	83	4,892	0
Common stock issued upon exercise of common stock warrants (in shares)		0	82,916,585
Deferred commitment fee for equity financing reclassified upon stock issuance	-518	0	0	-518	0
Loss on issuance of warrants	3,867	0	0	3,867	0
Series E convertible preferred stock issued, net of issue costs of $43	3,507	3,550	0	-43	0
Series E convertible preferred stock issued, net of issue costs (in shares)		3,944	0
Series E convertible preferred stock issued to retire demand promissory note	500	500	0	0	0
Series E convertible preferred stock issued to retire demand promissory note (in shares)		556	0
Series E convertible preferred stock deemed dividend from beneficial conversion feature	0	0	0	376	-376
Series D convertible preferred stock deemed dividend from beneficial conversion feature		330	0	0	-330
Series D convertible preferred stock reclassified to stockholdersb equity (deficit)	839	839	0		0
Series D convertible preferred stock reclassified to stockholdersb equity (deficit) (in shares)		1,299	0
Series E convertible preferred stock dividend accrued at period end	-65	0	0	0	-65
Series D convertible preferred stock 8% dividend accrued at period end	-65
Stock-based compensation expense	1,302	0	0	1,302	0
Net loss	-27,277	0	0	0	-27,277
Common stock issued in settlement of accounts payable (in shares)		0	37,500,000
Common stock issued upon conversion of convertible promissory notes, including accrued interest	130	0	7	123	0
Stock Issued During Period Shares Upon Conversion Of Convertible Promissory Notes Including Accrued Interest		0	6,937,801
Common stock issued for extension of maturity of demand promissory note payable	20		0	20	0
Common stock issued for extension of maturity of demand promissory note payable (in shares)			267,779
Balances at Dec. 31, 2014	($4,071)	$5,220	$842	$45,050	($55,183)
Balances (in shares) at Dec. 31, 2014		755,799	842,190,750

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Conversion, Converted Instrument, Rate	8.00%
Series D Preferred Stock [Member]
Preferred Stock, Dividend Rate, Percentage		8.00%
Series E Preferred Stock [Member]
Payments of Stock Issuance Costs	43

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net loss	($27,277)	($15,132)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	35	0
Amortization of debt discount	582	1,768
Amortization of deferred financing fees	223	253
Amortization of intangibles	118	70
Common Stock issued for services	663	860
Write-off of clinical trial materials	500	0
Impairment of investment	50	0
Loss on debt issuance	0	6,709
Loss on Common stock issuance	260	352
Loss on warrant issuance	3,867	0
Loss on extinguishment of convertible debt	1,250	0
Stock-based compensation expense	1,302	744
Non-cash interest expense	52	0
Change in fair value of warrants and derivative liabilities	-317	-271
Changes in assets and liabilities
Prepaid expenses and other current assets	-92	368
Accounts payable	4,645	88
Accrued expenses and accrued interest	-195	549
Related party liabilities	3	4
Net cash used in operating activities	-11,331	-3,473
Cash flows from investing activities
Restricted cash	-204	0
Investment	-50	0
Acquisition of property and equipment	-181
Acquisition of other assets and intangible assets	-1,100	-70
Net cash used in investing activities	-1,535	-70
Cash flows from financing activities
Proceeds from demand promissory notes	500	5,048
Repayment of demand and convertible notes, including accrued interest	-9	-304
Proceeds from issuance of common stock	3,074	0
Proceeds from issuance of convertible preferred stock	3,550	0
Proceeds from exercise of warrants	4,975	0
Costs of financings	-43	-325
Net cash provided by financing activities	12,047	4,419
Net (decrease) increase in cash and cash equivalents	-819	876
Cash and cash equivalents, beginning of period	1,033	157
Cash and cash equivalents, end of period	214	1,033
Supplemental schedule of non-cash activities:
Relative fair value associated with 8% senior convertible debentures issued with detachable warrants	0	1,939
Beneficial conversion feature - Series D convertible preferred stock	0	321
Convertible debentures and promissory notes	130	2,712
stock issued	516	0
Deferred commitment fee for equity financing reclassified upon stock issuance	-516	0
Preferred stock dividend accrued at end of period	-65	-26
Supplemental cash flow information
Interest paid	59	61
Convertible Notes Payable [Member]
Supplemental schedule of non-cash activities:
Debt discount associated with convertible promissory notes	0	813
Beneficial conversion feature - debt discount - convertible promissory notes	0	226
Debt discount written off - associated with convertible promissory notes	0	-250
Convertible Notes Payable [Member] \| Accounts Payable and Accrued Liabilities [Member]
Supplemental schedule of non-cash activities:
Convertible notes issued	0	123
Convertible Notes Payable [Member] \| Accounts Payable [Member]
Supplemental schedule of non-cash activities:
Convertible notes issued	0	161
Convertible Debt [Member]
Supplemental schedule of non-cash activities:
stock issued	0	1,559
Preferred stock Dividend [Member]
Supplemental schedule of non-cash activities:
stock issued	104	0
Common Stock [Member]
Cash flows from operating activities
Net loss	0	0
Supplemental schedule of non-cash activities:
Convertible debentures and promissory notes	7,091	0
Preferred stock dividend accrued at end of period		0
Common Stock [Member] \| Other Intangible Assets [Member]
Supplemental schedule of non-cash activities:
stock issued	354	79
Common Stock [Member] \| Accounts Payable and Accrued Liabilities [Member]
Supplemental schedule of non-cash activities:
stock issued	68	260
In Process Research and Development [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Conversion of Stock, Amount Converted	3,000	0
Series A Preferred Stock [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Conversion of Stock, Amount Converted		127
Series C Preferred Stock [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	0	39
Series D Preferred Stock [Member] \| Accounts Payable [Member]
Supplemental schedule of non-cash activities:
stock issued	0	1,169
Series E Preferred Stock [Member] \| Notes Payable, Other Payables [Member]
Supplemental schedule of non-cash activities:
stock issued	$500	$2,200

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature Of Operations [Text Block]		1	General

	Amarantus Bioscience Holdings, Inc. (the “Company”), is a biopharmaceutical company focused on the development of diagnostics and therapeutics to treat human disease, to date primarily in for Alzheimer's disease, Parkinson's disease and ophthalmological disorders. Through December 31, 2014, the Company has been primarily engaged in acquiring and licensing intellectual property and proprietary technologies, research and development, and raising capital to fund its operations.

LIQUIDITY_AND_GOING_CONCERN

LIQUIDITY AND GOING CONCERN	12 Months Ended
	Dec. 31, 2014
Liquidity And Going Concern [Abstract]
Liquidity And Going Concern [Text Block]		2	liquidity and Going Concern

	The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably. Our activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Historically, we have incurred net losses and negative cash flows from operations.

	The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. As of December 31, 2014, the Company had cash and cash equivalents of $214. Historically, the Company has incurred net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]		3	SIGNIFICANT ACCOUNTING POLICIES

	Principles of Consolidation - The consolidated financial statements include the accounts of Amarantus Bioscience Holdings, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated.

	Reclassification -Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.

	Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Significant estimates include the fair value of derivatives, the fair value of stock-based compensation and warrants, the carrying value of intangible assets (patents and licenses), valuation allowance against deferred tax assets, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

	Certain Significant Risks and Uncertainties - The Company participates in a global, dynamic, and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; regulatory approval and market acceptance of the Company’s products; development of the necessary manufacturing capabilities and the Company’s ability to obtain adequate resources of necessary materials; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees and other resources necessary to support its growth.

	Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company places its cash and cash equivalents with domestic financial institutions that are federally insured within statutory limits.

	Cash and Cash Equivalents - The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

	Restricted Cash – Cash restricted as to withdrawal or use is classified separately as restricted cash, and as current or non-current based upon the nature of the restriction.

	Property and Equipment - Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives as follows:

	Equipment	3 years
	Computer equipment	2 years
	Furniture and fixtures	3 years

	Intangible Assets – Intangible assets or certain rights to use certain intangible assets for the Company’s research and development activities are capitalized as assets in cases where the Company has determined that those assets have an identifiable alternative future use in accordance with GAAP. In certain cases, the Company may conclude certain assets have indeterminate useful lives in which case they are considered to have indefinite lives. The Company has determined that the useful lives of assets which can be reasonable estimated and amortized to expense over such useful lives range between 9.5 years and 18.5 years.

	Impairment of Long-Lived Assets – The Company reviews the carrying value of long-lived assets, including intangible assets and property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. There have been no impairments during the years ended December 31, 2014 and 2013.

	Research and Development Expenditures - Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, materials and supplies, licenses and fees, acquired in-process research and development, and overhead allocations consisting of various administrative and facilities related costs. Research and development activities consist primarily of three main categories: research, clinical development, and biotechnology development. Research costs typically consist of preclinical and toxicology costs. Clinical development costs include costs for clinical studies and trials. Biotechnology development costs consist of costs incurred for product formulation and analysis. Research and development costs are charged to expense when incurred.

	Fair Value of Financial Instruments - The fair value of certain of the Company’s financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which is not equivalent to cost will be classified and disclosed in one of the following three categories:

	• Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.

	• Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	• Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

	Stock-Based Compensation - Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

	Grant-date fair value is determined using the Black-Scholes option pricing model, which requires the use of the following assumptions:

	Expected Term — The expected term represents the period that awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

	Expected Volatility — Stock price volatility is computed over expected terms based on the historical common stock trading price of the Company’s common stock.

	Risk-Free Interest Rate — The risk-free interest rate is estimated based upon the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

	Expected Dividend — Cash dividends have never been declared or paid on common shares and there are no plans to do so in the foreseeable future such that the expected dividend yield is assumed to be zero.

	Forfeiture Rate — The forfeiture rate is based on historical data and managements estimates of failure rate to achieve vesting conditions. Forfeiture rates are adjusted as actual forfeitures differ from managements estimates for the awards that actually vest in the period of the change in estimate.

	The fair value of stock options granted to nonemployees is recognized over the period in which the related services are received.

	Preferred Stock - Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (‘mezzanine’) until such time as the conditions are removed or lapse.

	Convertible Financial Instruments – The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.

	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.

	Common Stock Purchase Warrants and Derivative Financial Instruments - Common stock purchase warrants and other derivative financial instruments are classified as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). Contracts which (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) that contain reset provisions that do not qualify for the scope exception are classified as assets or liabilities. The Company assesses classification of its common stock purchase warrants and other derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

	Debt Discounts - Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.

	Income Taxes - The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.

Interest and penalties related to uncertain tax positions are recorded in the provision for income tax expense on the consolidated statements of operations.

Net Loss Per Common Shareholder - Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options, warrants and restricted stock are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. In periods in which dilutive securities are considered antidilutive, they are excluded from the computation.

Recently Issued Accounting Pronouncements

Accounting Standards Update (ASU) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation removes all incremental financial reporting requirements for development stage entities, including the removal of reporting of the cumulative results of operations and cash flows for the period from inception to the end of the current period. The ASU is effective for the first annual period beginning after December 15, 2014. Early adoption is permitted, and the Company adopted this change during 2014.

ASU No. 2014-12, Compensation – stock requires that a performance target which affects vesting and could be achieved after the requisite service period should be treated as a performance condition that affects vesting, rather than a condition that affects the grant-date fair value. The ASU is effective for the first annual period beginning after December 15, 2015 and interim periods within those years for all entities. Early adoption is permitted. The Company is considering the effect of this FASB issuance, if any, on its financial statements. The Company has decided not to early adopt at this time.

ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this ASU are effective for the first annual period ending after December 15, 2016 and interim periods within those years for all entities. Early adoption is permitted. The Company is considering the effect of this FASB issuance, if any, on its financial statements. The Company has decided not to early adopt at this time.

ASU 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. The amendments in this ASU are effective for the first annual period ending after December 15, 2015 and interim periods within those years. Early adoption is permitted. The Company is considering the effect of this FASB issuance, if any, on its financial statements. The Company has decided not to early adopt at this time.

BALANCE_SHEET_DETAILS

BALANCE SHEET DETAILS	12 Months Ended
BALANCE SHEET DETAILS	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Balance Sheet Disclosures [Text Block]		4	balance sheet details

	Prepaid expenses and other current assets:		As of December 31,
			2014		2013
	Prepaid expenses		$	55	$	92
	Short-term deposits			97		—
	Other			46		14
	Total		$	198	$	106

	Property and equipment:		As of December 31,
			2014		2013
	Furniture		$	30	$	—
	Computer equipment, software, and other equipment			146		—
	Leasehold improvements			4		—
	Total property and equipment			180		—
	Accumulated depreciation			-35		—
	Total, net		$	145	$	—

	Accrued expenses:		As of December 31,
			2014		2013
	Accrued compensation and related benefits		$	58	$	266
	Dividends on Series D and E convertible preferred stock			91		26
	Total		$	149	$	292

	Related party liabilities:		As of December 31,
			2014		2013
	Promissory note, 2% interest		$	222	$	222
	Accrued interest			30		26
	Total		$	252	$	248

	The demand promissory note is due 365 days upon demand of the holder. At the option of the Company, the note and the accrued interest owed can be converted into common stock of the Company based on the closing price of the Company’s common stock on the day of the conversion. The conversion price if converted on December 31, 2014 would be $0.0822 related to the note and accrued interest on the note and would convert to approximately 3,071,000 shares.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]		5	Fair Value Measurements

	Fair value is defined under the standard as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The standard also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value

	The Company had no financial assets or liabilities measured at fair value on a recurring basis at December 31, 2014. Financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013, by level within the fair value hierarchy, are as follows:

			Level 1			Level 2		Level 3		Total
	Derivative liability			—			—		5,859		5,859

	Total fair value		$	—		$	—	$	5,859	$	5,859

	The derivative liability at December 31, 2013 represents the fair value of embedded conversion options associated with certain of the Company’s convertible notes, primarily the 8% senior convertible debentures as more fully described below. Additionally, these notes were all converted to common stock in 2014 as more fully described in Note 8.

	The following table summarizes the changes in the fair value of the Company’s Level 3 financial liabilities from January 1, 2013 to December 31, 2014:

			Warrant			Derivative
			Liability			Liability		Total
	1-Jan-13		$	233		$	27	$	260
	Issuance of convertible notes			—			8,582		8,582
	Reclass to additional paid in capital			—			-2,712		-2,712
	Change in fair value			-233			-38		-271
	31-Dec-13			—			5,859		5,859
	Conversion of 8% senior convertible debentures to common stock			—			-5,542		-5,542
	Change in fair value			—			-317		-317
	31-Dec-14		$	—		$	—	$	—

	The changes in fair value for all periods presented have been recorded in the accompanying consolidated statements of operations as a component of other income (expense).

	The fair value of the warrants at December 31, 2013 was determined using the Black-Scholes model with the following assumptions:

			2013
	Annualized volatility		331% - 335%
	Contractual life (years)		0.04
	Expected dividends		0%
	Risk-free investment rate		0.62 - 0.91%

	Derivative liability

	For certain convertible debt obligations, the Company recorded a related derivative liability representing the estimated fair value of embedded conversion options and remeasured the fair value at each reporting date.

	The fair values of the derivative liability measured at each reporting date and at conversion during 2014, and at December 31, 2013, were determined using the Black-Scholes model with the following assumptions:

			2014		2013
	Annualized volatility		78% - 138%		316% - 368%
	Contractual life (years)		0.08 – 0.67		0.03 - 0.93
	Expected dividends		0%		0%
	Risk-free investment rate		0.02% - 0.90%		0.01 - 0.12%

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	12 Months Ended
NET LOSS PER SHARE	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]		6	Net loss per share

	The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the periods indicated:

			Year Ended December 31,
			2014		2013
	Numerator
	Net loss		$	-27,277	$	-15,132
	Preferred stock dividend			875		38
	Net loss applicable to common stockholders		$	-28,152	$	-15,170

	Denominator
	Weighted average shares outstanding during the period:
	Common stock - basic			738,950,704		450,931,510
	Common shares equivalents			49,983,274		—
	Common stock - diluted			788,933,978		450,931,510

	Basic and diluted net loss per common share		$	-0.04	$	-0.03

	Potentially dilutive securities consist of:

			As of December 31,
			2014		2013
	Outstanding common stock options			30,196,127		6,941,288
	Outstanding preferred stock options			2,487,500		2,287,500
	Related party liabilities			3,070,663		3,107,356
	Warrants			46,636,722		84,553,306
	Convertible promissory note(s)			—		6,325,000
	8% senior convertible debentures			—		75,000,000
	Convertible preferred stock- Series C			750,000		750,000
	Convertible preferred stock- Series D			43,310,900		43,310,900
	Convertible preferred stock- Series E			56,250,000		—

	All of the listed dilutive securities are excluded from the computation of fully diluted loss per share as they are antidilutive.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
INTANGIBLE ASSETS	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]		7	intangible assets

	Intangible assets consist of:		As of December 31,
			2014		2013
	Intellectual properties			1,685	$	681
	Accumulated amortization			-188		-70
	Total intangible assets, net		$	1,497	$	611

	Intangible assets are amortized over the expected remaining useful lives. As of December 31, 2014, amortization expense for the next five years is expected to be as follows:

	2015		$	128
	2016			128
	2017			128
	2018			128
	2019			128
	Thereafter			857
	Total		$	1,497

CONVERTIBLE_DEBT

CONVERTIBLE DEBT (Convertible Debt [Member])	12 Months Ended
CONVERTIBLE DEBT (Convertible Debt [Member])	Dec. 31, 2014
Convertible Debt [Member]
Debt Disclosure [Text Block]		8	CONVERTIBLE DEBT

	The following summarize the Company’s convertible debt obligations:

	Convertible promissory notes
					Stated				Principal Balance Outstanding
					Interest				As of December 31,
	Issue Date		Maturity Date		Rate			Conversion Terms	2014		2013
	6/5/13			12/2/13		6	%	Fixed at $0.02		—	$	20
	11/4/12			5/3/13		6	%	Fixed at $0.01		—		10
	8/23/12			2/19/13		6	%	Fixed at $0.015		—		50
	Nov-12			On Demand		None		Refundable excess payment		—		1
	6/6/11			6/6/13		5	%	Variable at $0.04		—		10
	4/11/11			4/11/13		5	%	Variable at $0.04		—		25
	5/1/11			5/1/13		5	%	Fixed at $0.10		—		4
	4/1/11			4/1/13		5	%	Fixed at $0.10		—		4
	Total convertible promissory notes								$	—	$	124

	During 2014, all the convertible promissory notes consisting of $115 in principal and $14 in accrued interest were converted into approximately 6,938,000 shares of common stock and $9 in principal and $1 in accrued interest were paid in full to the note holders.

	8% Senior convertible debentures
					Stated				Principal Balance Outstanding
			Maturity		Interest				As of December 31,
	Issue Date		Date		Rate			Conversion Terms	2014		2013
	10/2/13			10/2/14		8	%	Variable conversion price	$	—	$	1,789
	9/6/13			9/6/14		8	%	Variable conversion price		—		1,544
	Total principal									—		3,333
	Discount on convertible promissory notes									—		-2,401
	8% senior convertible debentures, net								$	—	$	932

	During 2014, all the 8% senior convertible debentures consisting of $3,333 in principal and $125 of accrued interest converted into approximately 86,473,000 shares of common stock of the Company. Amortization of the discount through the date of conversion totaled $582 was recorded as other expense. A loss on conversion of the debt of $1,250 was also recorded as other expense as a result of the fair value the Company’s common stock at conversion exceeding the fair value of the debt, net of amortized discount and including the associated derivative liability.

	2013 Restructuring of Certain Convertible Debentures and Related Warrants

	In February 2013, the Company completed a series of transactions related to the restructuring of certain convertible debentures and related warrants that were in default. As a result, the Company executed two separate amended and restated Convertible Promissory Notes in the amounts of $375 and $187 (the “New Notes”), respectively, payable to Dominion Capital, LLC. The Company had defaulted on Promissory Notes issued in 2011 to certain individual investors in the total aggregate amount of $375 (the “Old Notes”), and related cashless warrants in the amount of $500. Dominion capital paid $563 to acquire the Old Notes, and as part of the transaction all of the related warrants were retired, inclusive of a $38 payment from the Company to certain warrant holders. The Old Notes and Related warrants had a conversion feature equal to a 66.6% floorless discount to a ‘Next Equity Financing’, defined as a financing where equity, or debt that was convertible into common stock, with a fixed price conversion feature. Such financing occurred, and as a result, $375 in notes became immediately convertible at a price of $0.015/share, equal to 25,000,000 common shares. The $188 was also priced at $0.015/share, however the note was not convertible for 6 months and the Company retained an option to repurchase this note at any time until maturity. The $188 note was converted into 12,500,000 common shares in July 2013.

	January 2013 Convertible Promissory Note Amendment

	In January 2013, the Company executed an amendment to a Convertible Promissory Note payable to Dominion Capital, LLC or its registered assigns (the “Dominion Note”), dated November 14, 2012, providing for an increase in the purchase price for such note from $600 to $2,000 to be disbursed in tranches through April 2013. The Dominion Note carried a stated interest rate of 10% per annum until paid in full and was convertible into shares of the Company’s common stock, subject to certain restrictions, at a price of $0.10 per share. The Dominion Note was amended to provide for an extended amortization schedule with a final maturity date of October 2013. The Company had the option to pay the Dominion Note in cash or stock at its discretion, subject to certain conditions. The Company received all $600 from the initial agreement in 2012, and received additional funding in 2013. The extended amortization schedule provided for payments of $200 to $250 every 2 weeks until the end of April 2013. The amended notes were converted in 2013 into 94,130,499 common shares.

DEMAND_PROMISSORY_NOTE

DEMAND PROMISSORY NOTE (Demand Deposits [Member])	12 Months Ended
	Dec. 31, 2014
Demand Deposits [Member]
Debt Disclosure [Text Block]	9	DEMAND PROMISSORY NOTE

	On February 14, 2014, the Company executed a Demand Promissory Note payable to Dominion Capital, LLC (“Demand Note”) in the amount of $500 at an annual interest rate of 12% compounded monthly until repayment. On March 12, 2014, the Company elected to extend the maturity of the Demand Note from March 14, 2014 to August 14, 2014. On August 14, 2014 and again on September 12, 2014 and October 12, 2014, the note holder agreed to extend the due date thirty days each time for a consideration of $10 in cash for the initial extension and $10 in common stock of the Company at each of the subsequent two extensions. The note was converted to Series E Preferred Stock prior to December 31, 2014.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	10	commitments and contingencies

	Commitments:

	Lease Arrangements

	The Company leases its main office facility and laboratory space in two separate locations in San Francisco, California. Office space in San Francisco is leased through November 2016 and provides for a monthly rental payment of approximately $12, plus operating expenses, subject to annual adjustment, of approximately $9 per month. The other facility lease is on a month-to-month basis.

	Future non cancellable minimum lease payments are:

	2015			146
	2016			139
	Total		$	285

	Rent expense for the years ended December 31, 2014 and 2013 was $150 and $30, respectively.

	Research License, and Option to License Arrangements —

	The Company is a party to various agreements which obligate it to make certain payments:

	PGI Drug Discovery, LLC (“PGI”) — Eltoprazine License and Services Agreements (January 2014)

	The Company entered into several agreements with PGI in 2014. Under the license agreements, the Company acquired rights to certain intellectual property covering the use of Eltoprazine and certain of its related compounds. In exchange, the Company paid PGI a total of $750 and 4,000,000 shares of common stock valued at $250 for which the Company granted piggy-back registration rights. The Company also has a contingent liability to pay PGI up to $4,000 upon achievement of future development milestone events: $1,000 at completion of a phase IIb study and $3,000 at submission of a New Drug Application (“NDA”) to the Food and Drug Administration (“FDA”) or comparable application to a non-U.S. agency.

	Simultaneously, the Company and PGI entered into a separate services agreement pursuant to which PGI will provide certain services related to PGI’s proprietary analytical systems, in exchange for cash payments totaling $450 at a minimum annual rate of $150 for each of three years, payable in equal quarterly installments. Also, the company purchased $500 of clinical trial material.

	The Washington University (“WashU”) — Sponsored Research (June 2014)

	The Company agreed to pay $120 to perform certain research of which $60 was paid in 2014. Wash U granted the Company (i) a non-exclusive, worldwide, royalty free license to utilize any inventions belonging solely to WashU conceived in WashU’s performance of the research plan (“WashU Inventions”), and (ii) an exclusive option to obtain an exclusive, worldwide license with a right to grant sublicenses to utilize any WashU Inventions or joint inventions upon terms to be negotiated.

	Buck Institute for Research on Aging (“Institute”) — Sponsored Research (August 2014)

	The Company agreed to pay $300, payable quarterly, to perform certain research of which $150 was paid in 2014.
	The Institute granted the Company (i) a non-exclusive, worldwide, royalty free license to utilize any institute inventions, sole or joint, for research purposes, and (ii) an exclusive option to obtain an exclusive, worldwide license with a right to sublicense to utilize any institute inventions, sole or joint upon terms to be negotiated.

	University of Miami (“U Miami”) — Sponsored Research (October 2014)

	The Company agreed to pay $155 to perform certain research payable in three installments, of which $52 was paid in 2014. On October 1 2014, the Company entered into a sponsored research agreement (the “Agreement”) with the University of Miami on the use of MANF in retinal disorders. The agreement calls for three equal payments of $52 on October 30, 2014, April 1, 2015 and upon receipt of the final written report.

	Acquiring Engineered Skin Substitute Intellectual Property - Lonza Walkersville

	In May 2014, we entered into discussions with Lonza Walkersville, Inc. (“Lonza) to acquire from Lonza its wholly owned subsidiary Cutanogen Corporation (“Cutanogen”), which is the licensee of certain Engineered Skin Substitute (“ESS”) intellectual property used to manufacture a product being developed to treat burn related injuries. At the time, Lonza was engaged in a lawsuit brought by Regenicin, Inc. relating to certain licensing rights associated with ESS. In order for the Company to acquire Cutanogen from Lonza, a resolution to the lawsuit was needed.

	On October 27, 2014, we entered into an Agreement (the “Lonza Option Agreement”) with Lonza pursuant to which we were granted an exclusive option to acquire Cutanogen (the “Option”). The terms of the acquisition are set forth in a draft Share Purchase Agreement (the “SPA”) that has been negotiated between the Company and Lonza. Pursuant to the SPA, we would purchase all of the shares of Cutanogen as well as certain assets of Lonza (the “Lonza Assets”) as listed in the draft SPA.

	As set forth in the SPA, and as consideration for the Cutanogen shares, we will make payments to Lonza, based upon the following milestone schedule:

		⋅	$4,000 upon execution of the SPA;
		⋅	$1,000 upon (i) successful completion of a Phase 1 clinical trial, or (ii) submission for a Humanitarian Use Exemption or similar exemption (“HUE”) for ESS (whichever occurs sooner); and
		⋅	$4,000 upon submission of a Biologic License Application to the Food and Drug Administration (“FDA”) or the approval of an HUE by the FDA or European Medicines Agency (“EMA”) (whichever occurs sooner).

	In addition, the Company will pay to Lonza two percent (2%) of Net Sales (as defined in the SPA) of each Earnout Product (as defined in the SPA).

	The company entered into an Option and Option amendments with Lonza that extended the Option period, and provided additional time for the Company to raise capital, and settle the Regenicin lawsuit. The Option and Option amendments provided that the Company would be required to make certain additional payments to Lonza, as described below. These payments are summarized below:

		⋅	$250 for the option period from November 7, 2014 to December 31, 2014,
		⋅	$400 for the option period from January 1, 2015 to February 28, 2015 and
		⋅	$300 for the option period from March 1, 2015 to March 31, 2015.

	On March 27, 2015, the Company entered into a third amendment to the Option that further extended the Option period from March 31, 2015 to August 31, 2015, on a month-by-month basis. In connection with this third amendment, the Company will make additional periodic payments to Lonza, a portion of which will fund Lonza’s continuing ESS development activity. Upon execution of this third amendment, the Company paid $350 to Lonza on March 31, 2015 and will pay the following additional amounts to Lonza until the earlier of such time as the Option is exercised or August 31, 2015:

		⋅	$400 on April 30, 2015 for the option period of April 1, 2015 to April 30, 2015,

		⋅	$600 on May 31, 2015 for the option period of May 1, 2015 to May 31, 2015,

	⋅	$600 on June 30, 2015 for the option period of June 1, 2015 to June 30, 2015 and

	⋅	$600 on July 31, 2015 for the option period of July 1, 2015 to July 31 2015

If the Company exercises the Option and consummates the SPA prior to any option payment being due, then no further payment(s) shall be required. In the event the SPA is not consummated, then the Company will incur a $1,000 break-up fee payable to Lonza.

The second step in the acquisition of ESS required the Company to enter into an Asset Purchase Agreement (the “Regenicin APA”) with Regenicin, Inc. (“Regenicin”) and other interested parties under which the Company agreed to acquire certain assets of Regenicin (the “Assets”), including (i) rights to the aforementioned lawsuit that Regenicin brought against Lonza (the “Litigation”), and (ii) all intellectual property rights held by Regenicin, related to any engineered skin technology for the treatment of severe burns in humans, including any related trademarks. The Regenicin APA was executed October 27, 2014. As consideration to Regenicin, the Company agreed to pay to Regenicin a total of $3,600 and 37,500,000 shares of Amarantus common stock. The shares were issued to Regenicin in November 2014 (valued at approximately $3,000), along with cash payments of $1,100. The remaining cash payments of $2,500 due to Regenicin under the Regenicin APA were paid by the end of February 2015. The asset purchase was recorded at its fair value as in-process research and development expense.

In addition to the Litigation and intellectual property noted above, the Company received from Regenicin an exclusive five (5) year option to license additional intellectual property related to severe burn products developed by Regenicin for an exercise price of $10,000 plus a royalty of 5% on gross revenues in excess of $150,000.

As a result of the Regenicin APA, the Company was able to acquire the Litigation, which it subsequently dismissed with prejudice. The Company is now able to pursue the execution of the Option and the SPA with Lonza to acquire Cutanogen.

Memory Dx, LLC (“MDx”)—Asset Purchase and License Agreement (April 2014)

In conjunction with a purchase agreement in which the Company purchased all assets of MDx, including intellectual property, dependent upon (i) the Company entering into a direct licensing agreement with the University of Leipzig (“Leipzig”) pursuant to which Leipzig would grant the Company a direct license to certain assets now licensed to MDx by Leipzig, and (ii) MDx terminating the license agreement it currently holds with Leipzig with the Company’s prior written consent, the Company will issue to MDx 6,500,000 shares of the Company’s common stock and will provide MDx with piggy-back registration rights for the shares.

Royalty Agreement — Founders
In October 2010, the Company entered into an agreement with the founders, Gerald Commissiong and John Commissiong, where they will receive a total of 2.5% royalty (1.25% each) from the gross commercial revenue of patents derived from the Company’s proprietary PhenoGuard platform technology, including patents associated with the MANF Protein and related Gene. To date no payments have been made as no milestones have been reached.

The Company has entered into other license agreements during 2014 which are cancellable at the option of the Company with no more than 90 days notice. In the event the agreements are in force at the time certain clinical trial and regulatory milestone events occur, the Company will be required to make certain payments, as well as royalties on future sales and patent costs. In some cases, the Company will pay an annual fee to be applied to milestone or royalty payments.

From time to time, the Company may become involved in litigation.

PREFERRED_STOCK

PREFERRED STOCK	12 Months Ended
PREFERRED STOCK	Dec. 31, 2014
Equity [Abstract]
Preferred Stock [Text Block]		11	PREFERRED STOCK

	Series A Convertible Preferred Stock

	In May 2012, the Company designated a class of preferred stock as Series A Convertible Preferred Stock. The Series A shares have no entitlement to dividends and have no voting rights. In any event of dissolution, liquidation or winding up of the Company, the Series A shares are entitled to receive a stated value of $1.00 per share. All distributions made to holders of the Series A shares and to holders of other stock of the Company upon liquidation shall be made on a pari passu basis with distributions made to holders of the Company’s common stock. The series A shares are convertible into the Company’s common stock at a stated conversion price that is equal to the lesser of 1) 110% of the closing common stock price on the date of conversion or 2) 80% of the lowest closing common stock price occurring during a 30 trading day period prior to notice of conversion. During 2013 the registered holder of the Company’s Series A convertible preferred stock converted all 250,000 shares into 8,094,117 shares of the Company’s common stock. The Series A Convertible Preferred Stock was converted in January 2013 as part of a services settlement with a vendor.

	Series B Preferred Stock

	On April 2, 2013 the Company filed a Certificate of Designation with the State of Nevada formally creating a series of Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock can only be issued to officers, directors and advisors of the Company, and cannot be converted into common stock, transferred, sold or disposed of in any manner for 24 months.

	Series C Convertible Preferred Stock

	On April 1, 2013, the Company filed a Certificate of Designation with the State of Nevada creating a series of Series C Convertible Preferred Stock. The Series C Convertible Preferred Stock can only be issued to officers and directors of the Company, is convertible into a cumulative total of 750,000 common shares and is automatically convertible into common stock upon listing of the Company’s common stock to a national stock exchange. The holders of Series C shares are entitled to 300 common stock equivalent votes per share on all corporate matters except those that by law only require a single series vote.

	Series D Convertible Preferred Stock

	On August 19, 2013, the Company entered into a securities purchase agreement with an institutional investor (the “Investor”) pursuant to which the Company issued shares of newly designated Series D Convertible Preferred Stock (”Series D Preferred Stock”) to the Investor in exchange for the Investor agreeing to paying off certain accounts payables of the Company, up to an aggregate approximate amount of $1,250.

	On August 19, 2013, the Company filed a Certificate of Designation designating 1,300 of our preferred stock as Series D Preferred Stock. Each share of Series D Preferred Stock has a stated value of $1,000 and pays on a quarterly basis 8% cumulative dividends per annum. Dividends are payable by the Company in cash or at the Company’s option, in shares of common stock. The Series D Preferred Stock has no voting rights except in certain circumstances which would adversely affect the Series D Preferred Stockholders. Each share of Series D Preferred Stock is convertible at any time into shares of common stock by dividing the stated value per share by the then effective conversion price. The conversion price for the Series D Preferred Stock is $0.03 per share, subject to adjustment under certain conditions. The Series D Preferred Stock is also subject to redemption by the Series D Preferred Stockholders upon certain triggering events. The redemption amount is equal to the greater of 130% of the stated value or the stated value divided by the then conversion price multiplied by the volume weighted average price (“VWAP”) on the trading day immediately preceding the triggering event, plus any accrued and unpaid dividends. The redemption payment may, at the option of the holder, be in cash or shares. Redemption triggering events may include certain events such as change of control, bankruptcy, junior security redemptions, common stock shall fail to be listed or quoted on a Trading Market for more than five Trading Days, or other adverse events as described under the agreement. Series D Preferred Stock also has a liquidation preference equal to the Stated Value.
	No triggering event has occurred.

	On June 30, 2014, with the approval of the holder of the Company’s Series D Preferred Stock, the Company filed an amendment to the Certificate of Designation of the Series D Preferred Stock to amend remove the feature by which stockholder could require redemption of the stock at cost. Accordingly, since the Series D Preferred Stock now contains mainly equity-like features, the Company changed the classification of the stock on its balance sheet from temporary equity to permanent equity within stockholders’ equity (deficit).

	The securities were issued at 10% discount and contain a beneficial conversion feature. The beneficial conversion feature has been accreted, resulting in a deemed dividend reflected in the December 31, 2014 Consolidated Statements of Stockholders’ Equity (Deficit). The value of the original issue discount is $130 and the beneficial conversion feature is $321.

	Series E Convertible Preferred Stock

	On November 7, 2014, the Company entered into securities purchase agreements pursuant to which the Company issued 4,500 shares of Series E Convertible Preferred Stock (”Series E Preferred Stock”) which has a stated value of $1,000 and pays quarterly 12% cumulative dividends per annum. Dividends are payable by the Company in cash or at the Company’s option, in shares of common stock if certain conditions are met. These conditions include availability of funds or no occurrence of a triggering event. Triggering events include change of control, bankruptcy, junior security redemptions, common stock shall fail to be listed or quoted on a Trading Market for more than five Trading Days. No triggering event has occurred.

	Holders of Series E shares are entitled to three years of dividends even if converted up to three years following the issuance date. Each share of Series E Preferred Stock is convertible into shares of common stock by dividing the stated value per share by the then effective conversion price. The conversion price for the Series E is $0.08 per share, subject to adjustment under certain conditions, but in no event prior to six months from issuance. Series E Preferred stockholders have the right to vote on all matters submitted to the Company’s shareholders and the Series E Preferred Stock are entitled to such number of votes on an as-converted basis. Series E Preferred Stock also has a liquidation preference equal to the stated value and accrued and unpaid dividends.

	During 2014, the Company sold 3,944 shares of Series E Preferred Stock for proceeds of $3,507, net of issuance costs of $43. The Company also issued 556 shares to retire a $500 demand promissory note.

	The securities were issued at 10% discount and contain a beneficial conversion feature. The beneficial conversion feature has been accreted, resulting in a deemed dividend reflected in the December 31, 2014 Consolidated Statements of Stockholders’ Equity (Deficit). The value of the original issue discount is $450 and the beneficial conversion feature is $376.

	Preferred Stock Dividends

	As described in Note 11, Preferred Stock, certain of the Company’s outstanding preferred stockholders are entitled to a certain amount of dividends even if converted.

	Common Stock Purchase Warrants

	The following table summarizes the Company’s warrant activity for the years ended December 31, 2013 and December 31, 2014:

					Weighted		Weighted Average
				Number of	Average		Remaining
				Warrants	Exercise Price		Contractual Term
	Outstanding as of December 31, 2012			12,584,829	$	0.04	4.74
	Issued in connection with convertible debt offerings			83,333,250		0.06
	Exercised			—		—
	Cancelled			-11,364,773		0.04
	Outstanding as of December 31, 2013			84,553,306	$	0.06	2.69
	Issued in connection with warrant exchange			45,000,000		0.12
	Exercised			-82,916,584		0.06
	Outstanding (exercisable) as of December 31, 2014			46,636,722	$	0.12	4.06

	The warrants issued in 2013 are exercisable for a term of three years from the date of issuance at an exercise price of $0.06 per share and exercisable on a cashless basis if at any time after the six month anniversary there is no effective registration statement or current prospectus available for the resale of the shares underlying the warrants.

	Warrant Exchange

	Pursuant to an offer to exercise dated February 13, 2014 as supplemented on March 6, 2014, holders of outstanding warrants at a price of $0.06 (“Original Warrants”) were offered the opportunity to exercise their Original Warrants and receive new warrants (“New Warrants”) to purchase three shares of common stock of the Company for every four Original Warrants exercised. On March 7, 2014, warrant holders exercised 60,000,000 Original Warrants and received New Warrants to purchase 45,000,000 shares of common stock of the Company.

	The New Warrants are exercisable at a price of $0.12 for a term of five years. The New Warrants are callable by the Company if the Volume Weighted Average Price (VWAP) of the Company’s common stock for each of 20 consecutive trading days exceeds $0.18 and certain equity conditions are met. The Company may also call the New Warrants if the closing price of the Company’s common stock exceeds $0.18 on the date that is the earlier of the receipt by the Company of an approval letter for listing of the Company’s common stock on an exchange or listing of the common stock on an exchange. The holders of the New Warrants will also have piggy-back registration rights.

	The Company recorded a loss on issuance of $3,867 in other expense for the warrant exchange based on the fair value of the warrants. The fair value was determined to be using the Black-Scholes model with the following assumptions which the Company believes approximates the fair value under a binomial lattice model:

Annualized volatility ⁽¹⁾		305	%
Contractual term		5
Risk-free investment rate		1.65	%
Dividend yield		0	%

COMMON_STOCK

COMMON STOCK	12 Months Ended
COMMON STOCK	Dec. 31, 2014
Equity [Abstract]
Common Stock Note Disclosure [Text Block]		12	COMMON STOCK

	The Company is authorized to issue 2,000,000,000 shares of common stock, $0.001 par value. The holders of common stock: (i) have equal rights to dividends from funds legally available therefore, ratably when as and if declared by the Company’s Board of Directors; (ii) are entitled to share ratably in all assets of the Company available for distribution to holders of common stock upon liquidation, dissolution, or winding up of the affairs of the Company; (iii) do not have preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions applicable thereto; (iv) are entitled to one non-cumulative vote per share of common stock, on all matters which shareholders may vote on at all meetings of shareholders; and (v) the holders of common stock have no conversion, preemptive or other subscription rights. There is no cumulative voting for the election of directors. Each holder of our common stock is entitled to one vote for each share of our common stock held on all matters submitted to a vote of stockholders. As of December 31, 2014, our Board of Directors had declared no dividends payable to holders of our common stock.

	Common stock private placement

	In March 2014, the Company entered into an equity financing agreement (“LPC Purchase Agreement”) with Lincoln Park Capital Fund LLC (“LPC”) whereby LPC is obligated to purchase up to $20,000 of the Company’s common stock from time to time over a 30 month period, as directed by the Company and subject to certain requirements, restrictions and limitations. Under the LPC Purchase Agreement, the per share purchase price will be the lesser of the lowest sale price of common stock on the purchase date or the average of the three lowest closing purchase prices during the ten consecutive business days prior to the purchase date. However, LPC is not obligated to purchase shares from the Company on any date that the closing price of the common stock is below $0.04, subject to adjustment upon the occurrence of certain stock related events. The Company may also request that LPC purchase shares under an accelerated purchase notice whereby the per share purchase price will be the lower of (i) 94% of a volume weighted average price calculation as determined under the LPC Purchase Agreement or (ii) the closing price of the common stock on the accelerated purchase date.

	Concurrently with the execution of the LPC Purchase Agreement, LPC purchased an initial 4,000,000 shares for gross proceeds of $400.
	In consideration for entering into the LPC Purchase Agreement, the Company will issue 9,500,000 shares of common stock to LPC (the ‘Commitment Fee Shares’), 6,000,000 of which upon entering into the agreement and 3,500,000 contingently issuable on a pro rata basis as the Company utilizes the financing arrangement. The agreement will automatically terminate upon the earlier of 30 months (August 2016) or upon full utilization of the purchase commitment.

	Issuances through December 31, 2014 and the remaining available amounts under the financing agreement:

			Commitment				Financing
			Fee Shares		Shares Sold		Available
	Total under agreement			9,500,000			$	20,000
	Issued at execution			-6,000,000		4,000,000
	Issued subsequent to execution			-468,001		26,041,120		-2,674
	Total activity			-6,468,001		30,041,120		-2,674
	Available for issue at December 31, 2014			3,031,999			$	17,326

	The fair value of the 6,000,000 Commitment Fee Shares initially issued to LPC was approximately $516 at issue and initially recorded as a deferred funding fee asset. The fee, as well as fair value at issue of subsequent Commitment Fee Shares, has been recognized as additional paid in capital as of December 31, 2014.

STOCK_OPTION_PLANS

STOCK OPTION PLANS	12 Months Ended
STOCK OPTION PLANS	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]		13	Stock option planS

	2008 Stock Plan

	The Company’s Board of Directors approved the 2008 Stock Plan (the “Plan”). Under the Plan, the Company may grant up to 46,119,832 shares of incentive stock options, nonqualified stock options, or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years.

	The following table is a summary of activity under the 2008 Plan:

									Weighted
			Common						Average		Aggregate
			stock						Remaining		Intrinsic
			options						Contractual		Value
			outstanding				Weighted Average Exercise Price ($)		Term (years)		$0
	Balance – December 31, 2012			1,829,026		$	0.02			6.4
	Options granted (weighted-average fair value of $0.52)
	Employee			776,924			0.05			9.2
	Non-employee			5,746,155			0.05			9.2
	Options cancelled			-1,210,817			0.01			—
	Options exercised			-200,000			0.05			—
	Balance December 31, 2013			6,941,288			0.05			9	$	0
	Options granted (weighted-average fair value of $0.08)
	Employee (1)			12,500,000			0.09			9.3
	Non-employee			3,301,323			0.08			9.3
	Options cancelled			-1,146,484			0.07			—
	Options exercised			—			—			—
	Balance December 31, 2014			21,596,127		$	0.08			8.8	$	47

	Options vested December 31, 2014			16,303,994

		-1	Includes 4,000,000 shares granted to Robert Farrell, the Company’s Chief Financial Officer, 2,000,000 of which are performance-based and vest upon continued service and achievement of a specific goal; and 2,000,000 of which are market-based and vest upon continued service and the Company’s achievement of certain stock price targets. All of these shares have an exercise price of $0.08.

	The amount of awards available to grant under the Plan is 1,346,484 as of December 31, 2014.

	2014 Stock Plan

	In August 2014, the Company adopted the 2014 Stock Plan (the “2014 Plan”), which was approved by the Company’s stockholder at the Company’s Annual Meeting in September 2014. Under the 2014 Plan, the Company may grant up to 153,880,168 common shares in the form of incentive stock options, nonqualified stock options or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years.

	The following table is a summary of activity under the 2014 Plan:

			Common		Weighted Average		Weighted
			Stock		Exercise Price ($)		Average
			options				Remaining
			outstanding				Contractual
							Term (years)
	Balance – December 31, 2013		—		—		—
	Options granted (weighted-average fair value of $0.09)
	Employee		8,600,000		0.09		9.8
	Non-Employee		—		—		—
	Options cancelled		—		—		—
	Options Exercised		—		—		—
	Balance December 31, 2014		8,600,000		0.09		9.8

	Options vested as of December 31, 2014		716,016

	The amount of awards available to grant under the 2014 Plan is 145,280,168 as of December 31, 2014.

	2012 Preferred Stock Plan

	In July 2012, our Board of Directors adopted a new stock plan, the Management, Employee, Advisor and Director Preferred Stock Option Plan – 2012 Series B Convertible Preferred Stock Plan (“Preferred Stock Plan”). The purposes of the Preferred Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Management, Employees, Advisors and Directors and to promote the success of our business. Certain current and former Management, Employees, Advisors and Directors were awarded a total of 1,248,000 options to purchase Series B Preferred shares on July 15, 2012, and an additional 1,200,000 options on November 4, 2012. These options currently vest over four years and cannot be converted into common shares or sold for two years from the date of the Designation of the Series B Preferred shares. Each share of Series B Preferred stock converts into fifty shares of common stock. The following table is a summary of activity under the Preferred Stock Plan:

									Weighted
			Preferred						Average
			Stock						Remaining
			Options			Weighted Average			Contractual
		Outstanding			Exercise Price ($)			Term (years)
Balance – December 31, 2012			2,448,000			0.46			9.6
Preferred options granted (weighted-average fair value of $0.0237)
Employee			—			—			—
Non-employee			—			—			—
Preferred options cancelled			-160,500			0.23			—
Balance – December 31, 2013			2,287,500			0.47			8.5
Preferred options granted (weighted-average fair value of $1.61)
Employee			200,000			2.21			9.3
Non-employee			—			—			—
Preferred options cancelled			—			—			—
Balance – December 31, 2014			2,487,500		$	0.61			8.1

Preferred options vested at December 31, 2014			1,986,068

The amount of awards available to grant under the Preferred Stock Plan is 512,500 as of December 31, 2014.

Stock-based compensation expense for all plans for the years ended December 31, 2014and 2013 is classified in the statements of operations as follows:

		Year Ended December 31,
		2014			2013
Research and development		$	412		$	338
General and administrative			890			406
Total		$	1,302		$	744

At December 31, 2014, there was a total of $1,510 of unrecognized compensation cost net of estimated forfeitures related to un-vested stock-based awards, which is expected to be recognized over a weighted-average period of approximately 2.5 years.

The fair value of the Company’s stock-based awards during the twelve months ended December 31, 2014 and 2013 were estimated using the following assumptions:

	Year Ended December 31,
			2014			2013
Weighted-average volatility			288	%		90	%
Weighted-average expected term			5.8			5
Expected dividends			0	%		0	%
Risk-free investment rate			2	%		2	%
Expected forfeiture rate			0	%		0	%

INCOME_TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]		14	INCOME TAXES

	There is no provision for income taxes because we have incurred operating losses since inception and applied a full valuation allowance against all deferred tax assets. The reported amount of income tax expense attributable to operations for the year differs from the amount that would result from applying domestic federal statutory tax rates to loss before income taxes from operations as summarized below:

			Year ended December 31,
	Loss before income taxes		2014			2013
	United States		$	-27,278		$	-15,132
	Foreign			—			—
	Total Income (Loss) before income taxes		$	-27,278		$	-15,132

	Income tax expense (benefit) for the years ended December 31, 2014 and 2013 differed from the amounts computed by applying the statutory federal income tax rate of 34% to pretax income (loss) as a result of the following:

			Year ended December 31,
			2014			2013
	Federal tax expense (benefit) at statutory rate		$	-9,274		$	-5,145
	State tax expense (benefit), net of federal tax effect			-1,334			-539
	R&D credit			-269			-46
	Non-deductible expenses			1,696			2,192
	Change in valuation allowance			9,181			3,538
	Total tax expense		$	—		$	—

			Year ended December 31,
			2014				2013
	Federal tax expense (benefit) at statutory rate			-34	%			-34	%
	State tax expense (benefit), net of federal tax effect			-4.9	%			-3.6	%
	R&D credit			-1	%			-0.3	%
	Non-deductible expenses			6.2	%			14.5	%
	Change in valuation allowance			33.7	%			23.4	%
	Total tax expense			—	%			—	%

	The significant components of deferred tax assets are as follows:

			As of December 31,
			2014			2013
	Net operating loss carry-forward		$	12,835		$	7,320
	Tax credit carry-forward			504			204
	Accrued liabilities			1,257			723
	Capitalized start-up costs			15			15
	Depreciation and amortization			2,833			1
	Gross deferred tax assets			17,444			8,263
	Valuation allowance			-17,444			-8,263
	Net deferred tax assets		$	—		$	—

	The Company’s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company’s net deferred tax assets. The Company primarily considered such factors as the Company’s history of operating losses, the nature of the Company’s deferred tax assets and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying balance sheets. The valuation allowance increased by approximately $9,181 and $3,538 during the years ended December 31, 2014 and December 31, 2013, respectively.

	As of December 31, 2013, the Company had net federal and state net operating loss carry-forwards of approximately $18,374 and $18,378, respectively. These net operating loss carry forwards will begin to expire, if not utilized, beginning in 2028 for both federal and state income tax purposes. The Company also has federal and state research and development credit carry-forwards of approximately $134 and $141, respectively. The federal credits will expire if not utilized beginning in 2029. The California credits do not expire. As of December 31, 2014, the Company had net federal and state net operating loss carry-forwards of approximately $32,226 and $32,190, respectively. These net operating loss carry forwards will begin to expire, if not utilized, beginning in 2028 for both federal and state income tax purposes. The Company also has federal and state research and development credit carry-forwards of approximately $398 and $193, respectively. The federal credits will expire if not utilized beginning in 2029. The California credits do not expire.

	The Tax Reform Act of 1986 and similar California legislation impose substantial restrictions on the use of net operating losses and tax credits in the event of an ownership change of a corporation. Accordingly, the Company’s ability to use net operating losses and credit carry forwards may be significantly limited in the future as a result of such an ownership change.

	The Company follows GAAP with regard recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. No liability related to uncertain tax positions is recorded on the financial statements. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of tax expense, as necessary.

	A summary of unrecognized tax benefits is as follows:

	Ending balance at December 31, 2012		$	17
	Increase (decrease) of unrecognized tax benefits taken in prior years			—
	Increase (decrease) of unrecognized tax benefits related to current year			10
	Increase (decrease) of unrecognized tax benefits related to settlements			—
	Reductions to unrecognized tax benefits related lapsing statute of limitations			—

	Ending balance at December 31, 2013		$	27
	Increase (decrease) of unrecognized tax benefits taken in prior years			—
	Increase (decrease) of unrecognized tax benefits related to current year			35
	Increase (decrease) of unrecognized tax benefits related to settlements			—
	Reductions to unrecognized tax benefits related lapsing statute of limitations			—

Ending balance at December 31, 2014		$	62

The total amount of unrecognized tax benefits that if recognized, would affect the effective tax rate is $0.

The Company has not incurred any interest or penalties as of December 31, 2014. The Company does not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions. The Company is subject to taxation in the US and California. There are no ongoing examinations by taxing authorities at this time.

The Company’s tax years 2008 through 2014 will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss credits.

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]		15	Related-Party Transactions

	Consulting Agreement –Director
	The Company has an agreement with a NeuroAssets Sarl, a Swiss-based company to provide consulting services to the Company. Dr. David Lowe was appointed to the Company’s Board of Directors in November 2013 and is the president and chief executive officer of NeuroAssets. The Company recorded $660 and $350 in consulting fees to NeuroAssets for the years ended December 31, 2014 and 2013, respectively.

	The Company has an agreement with Joseph Rubinfeld to provide consulting services to the company. Joseph Rubinfeld was appointed to the Company’s Board of Directors in November 2012. The company recorded $142 and $10 in consulting fee for the years ended December 31, 2014 and 2013, respectively.

	Related Party Debt and Capital Transactions
	At December 31, 2013, one of the Company’s Directors, Robert Harris, held $66 of convertible promissory notes with the Company. The notes were converted during 2014 such that a total of 4,990,925 shares of common stock were issued for principal and accrued interest.

	In October 2013, the Company’s Chief Executive Officer, Gerald Commissiong, its Chief Scientific Officer, John Commissiong and one of the Company’s Directors Robert Harris invested $5 each or an aggregate of $15 in total and was each issued an 8% senior convertible debenture in the principal aggregate amount of $6 and a warrant to purchase 138,889 shares. Each of the debentures was converted to shares of common stock during 2014 such that a total of 147,265 shares of common stock were issued to each Messrs. Gerald Commissiong and John Commissiong for principal and accrued interest. The shares underlying the debentures and warrants purchased by Messrs. Gerald Commissiong, John Commissiong and Robert Harris were not included in the related registration statement.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16	SUBSEQUENT EVENTS

	The Company evaluated subsequent events through the date that its financial statements were available for issuance.

	Common Stock Purchase Agreement
	Through March 25, 2015, the Company has sold an additional 37,445,801 shares of common stock for gross proceeds of $2,767 under its agreement with LPC, and issued an additional 484,248 Commitment Fee shares.

	Series D Convertible Stock

		·	On March 11, 2015 Dominion Capital exercised 299 Series D shares to 9,977,567 common shares.
		·	On March 25, 2015 Dominion Capital exercised 250 Series D shares to 8,333,333 common shares.

	Series E Convertible Preferred Stock

	Through March 31 2015, the Company has sold an additional 3,278 shares of Series E convertible preferred stock for gross proceeds of $2,950.

	On March 4, 2015 Dominion Capital LLC converted 500 Series E shares to 6,250,000 common shares as well as 2,375,624 Make-Whole shares.

	On April 2, 2015, the Company filed an amended and restated Certificate of Designation of its Series E Preferred Stock (The “Amendment”). The Amendment increased the number of authorized Series E Preferred Stock from 7,779 to 13,335 and changed the conversion price for the Series E Preferred Stock from $0.08 to $0.05, subject to adjustments, provided no adjustments shall be made until October 31, 2015

	The Amendment also provides that simultaneously with the consummation of a Qualified Public Offering (defined in the Amendment as a public offering for gross proceeds of at least $10,000,000 and listing on a national securities exchange) each share of outstanding Series E Preferred Stock, together with any unpaid Dividends shall be converted into shares of Common Stock of the Company subject to adjustments at a conversion price per share of Series E Preferred Stock equal to the lower of $0.05 or 85% of the public offering price of the Qualified Public Offering (“Mandatory Conversion Price”). In addition, 30% (25% if no warrants are sold to the public in the Qualified Public Offering) of the Stated Amount of the outstanding Preferred Stock together with any Make-Whole Amount shall, at the Company’s option, in whole or in part, be paid in cash or in shares of common stock priced at the Mandatory Conversion Price.

	As consideration for the agreeing to the Amendment, the existing Series E Preferred Shareholders received, an aggregate of 30,000,000 shares of common stock pro rata to the Stated Value of Series E Preferred Stock then held by each holder.

	DioGenix Acquisition
	On January 8, 2015, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with DioGenix, Inc., a Delaware corporation (“DioGenix”), in which the Company acquired all of the outstanding equity interests of DioGenix. Total consideration for the acquisition is 99,378,881 shares of the Company’s common stock and up to $2,000 in additional payments to DioGenix stockholders in cash or combination of cash and common stock, conditioned on the achievement of certain milestones related to results of clinical testing and future revenue from products in development. A portion of the consideration will be placed into escrow to satisfy certain indemnification obligations of DioGenix stockholders. The shares of the Company issued may, upon the request of the Company, be made subject to lock-up agreements precluding sale of such shares as described in the Merger Agreement. The company will obtain a report from a valuation specialist, pro forma information is currently not available.

	The Merger Agreement also includes registration rights whereby the Company will file a registration statement with the Securities and Exchange Commission covering the consideration paid with common stock within 120 days of the closing of the transaction, subject to certain terms and conditions, including certain penalties to the Company for delay in registering the shares.

	The Company incurred approximately $500 of transaction fees at closing.

	Note payable

	On February 23, 2015, the Company entered into a Securities Purchase Agreement with Dominion Capital pursuant to which the Company issued a 12% Promissory Note (the “February Note”) in the principal amount of $2,500 due and payable on December 23, 2015 in cash or stock or a combination at The Company’s option. At any time upon ten (10) days written notice to Dominion Capital, the Company may prepay any portion of the principal amount of the Note and any accrued and unpaid interest at an amount equal to 110% of the then outstanding principal amount of the Note and guaranteed interest, 10% of which may be paid in cash or, at the Company’s option, in common stock or a combination thereof.

	The February Note contains certain customary Events of Default (including, but not limited to, default in payment of principal or interest thereunder, breaches of covenants, agreements, representations or warranties thereunder, the occurrence of an event of default under certain material contracts of the Company, including the transaction documents relating to the Note transaction, changes in control of the Company and the entering or filing of certain monetary judgments against the Company). Upon the occurrence of any such Event of Default the outstanding principal amount of the February Note, plus accrued but unpaid interest, liquidated damages, and other amounts owing in respect thereof through the date of acceleration, shall become, at the Investor’s election, immediately due and payable in cash. Upon any Event of Default that results in acceleration of the February Note, the interest rate on the Note shall accrue at an interest rate equal to the lesser of 24% per annum or the maximum rate permitted under state law at the time of the default..

	In connection with the February Note Transaction, effective on February 23, 2015, the Company entered into a Security Agreement with the Investor (the “Security Agreement”) pursuant to which the Company granted a security interest in certain of its property (the “Collateral”) to Dominion Capital in order to secure the prompt payment, performance and discharge in full of all of the Company’s obligations under the Note. The Collateral shall consist of all of the Company’s rights, title and interest in and to that certain Asset Purchase Agreement, dated November 7, 2014, by and among the Company, Regenicin, Inc., Clark Corporate Law Group, LLP, and Gordon& Rees, LLP and that certain Option Agreement, dated November 7, 2014, by and between the Company and Lonza Walkersville.

	As part of the financing, Dominion received 1,250,000 shares of the Company’s restricted common stock valued at $98.

	On March 31, 2015, the Company issued an additional Note to Dominion in the principal amount of $350. The March Note was issued upon the same terms and conditions as the February Note.

	Georgetown University Option to License
	On January 13, 2015, the Company entered into an Exclusive Option Agreement (the “GU Option Agreement”) with the Georgetown University (“GU”) pursuant to which the Company was granted an option to obtain an exclusive license (with the right to sublicense) from Georgetown based upon certain patented technologies entitled “BLOOD BASED BIOMARKERS FOR MEMORY LOSS” (the “Technologies”). The term of the option is 12 months which may be extended mutual written consent of the parties. In consideration for the grant of the option, the Company paid an option fee of $75.

	Prior to exercise of the option, the Company must (i) satisfy certain milestones as further described in the Agreement, (ii) obtained financing of at least $10,000 of which $3,000 shall be used to commercialize the Technologies, (iii) shall have sponsored at least $500 worth of research at Georgetown throughout the course of the term of the Agreement, and (iv) has submitted, to GU, a business plan for commercialization of the Technologies.

	The Agreement contemplates that the parties, upon exercise of the Option, will use good faith efforts to execute a license agreement within 120 days of the exercise of the Option.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation - The consolidated financial statements include the accounts of Amarantus Bioscience Holdings, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Reclassification, Policy [Policy Text Block]	Reclassification -Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.

Use of Estimates, Policy [Policy Text Block]	Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Significant estimates include the fair value of derivatives, the fair value of stock-based compensation and warrants, the carrying value of intangible assets (patents and licenses), valuation allowance against deferred tax assets, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Certain Significant Risks And Uncertainties [Policy Text Block]	Certain Significant Risks and Uncertainties - The Company participates in a global, dynamic, and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; regulatory approval and market acceptance of the Company’s products; development of the necessary manufacturing capabilities and the Company’s ability to obtain adequate resources of necessary materials; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees and other resources necessary to support its growth.

Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company places its cash and cash equivalents with domestic financial institutions that are federally insured within statutory limits.

Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents - The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash – Cash restricted as to withdrawal or use is classified separately as restricted cash, and as current or non-current based upon the nature of the restriction.

Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment - Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives as follows:

	Equipment	3 years
	Computer equipment	2 years
	Furniture and fixtures	3 years

Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Intangible Assets – Intangible assets or certain rights to use certain intangible assets for the Company’s research and development activities are capitalized as assets in cases where the Company has determined that those assets have an identifiable alternative future use in accordance with GAAP. In certain cases, the Company may conclude certain assets have indeterminate useful lives in which case they are considered to have indefinite lives. The Company has determined that the useful lives of assets which can be reasonable estimated and amortized to expense over such useful lives range between 9.5 years and 18.5 years.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets – The Company reviews the carrying value of long-lived assets, including intangible assets and property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. There have been no impairments during the years ended December 31, 2014 and 2013.

Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenditures - Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, materials and supplies, licenses and fees, acquired in-process research and development, and overhead allocations consisting of various administrative and facilities related costs. Research and development activities consist primarily of three main categories: research, clinical development, and biotechnology development. Research costs typically consist of preclinical and toxicology costs. Clinical development costs include costs for clinical studies and trials. Biotechnology development costs consist of costs incurred for product formulation and analysis. Research and development costs are charged to expense when incurred.

Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments - The fair value of certain of the Company’s financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which is not equivalent to cost will be classified and disclosed in one of the following three categories:

	• Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.

	• Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	• Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation - Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

	Grant-date fair value is determined using the Black-Scholes option pricing model, which requires the use of the following assumptions:

	Expected Term — The expected term represents the period that awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

	Expected Volatility — Stock price volatility is computed over expected terms based on the historical common stock trading price of the Company’s common stock.

	Risk-Free Interest Rate — The risk-free interest rate is estimated based upon the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

	Expected Dividend — Cash dividends have never been declared or paid on common shares and there are no plans to do so in the foreseeable future such that the expected dividend yield is assumed to be zero.

	Forfeiture Rate — The Company estimated forfeitures related to option grants at a weighted average annual rate of 0% per year, as the Company does not yet have adequate historical data, for options granted during the years ended December 31, 2014 and 2013.
	The fair value of stock options granted to nonemployees is recognized as stock-based compensation expense over the period in which the related services are received.

Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	Preferred Stock - Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (‘mezzanine’) until such time as the conditions are removed or lapse.

Convertible Instruments [Policy Text Block]	Convertible Financial Instruments – The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.

	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.

Common Stock Purchase Warrants And Derivative Financial Instruments [Policy Text Block]	Common Stock Purchase Warrants and Derivative Financial Instruments - Common stock purchase warrants and other derivative financial instruments are classified as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). Contracts which (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) that contain reset provisions that do not qualify for the scope exception are classified as assets or liabilities. The Company assesses classification of its common stock purchase warrants and other derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

Debt, Policy [Policy Text Block]	Debt Discounts - Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.

Income Tax, Policy [Policy Text Block]	Income Taxes - The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

	In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.

	Interest and penalties related to uncertain tax positions are recorded in the provision for income tax expense on the consolidated statements of operations.

Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Common Shareholder - Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options, warrants and restricted stock are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. In periods in which dilutive securities are considered antidilutive, they are excluded from the computation.

New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements

	Accounting Standards Update (ASU) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation removes all incremental financial reporting requirements for development stage entities, including the removal of reporting of the cumulative results of operations and cash flows for the period from inception to the end of the current period. The ASU is effective for the first annual period beginning after December 15, 2014. Early adoption is permitted, and the Company adopted this change during 2014.

	ASU No. 2014-12, Compensation – stock requires that a performance target which affects vesting and could be achieved after the requisite service period should be treated as a performance condition that affects vesting, rather than a condition that affects the grant-date fair value. The ASU is effective for the first annual period beginning after December 15, 2015 and interim periods within those years for all entities. Early adoption is permitted. The Company is considering the effect of this FASB issuance, if any, on its financial statements. The Company has decided not to early adopt at this time.

	ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this ASU are effective for the first annual period ending after December 15, 2016 and interim periods within those years for all entities. Early adoption is permitted. The Company is considering the effect of this FASB issuance, if any, on its financial statements. The Company has decided not to early adopt at this time.

	ASU 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. The amendments in this ASU are effective for the first annual period ending after December 15, 2015 and interim periods within those years. Early adoption is permitted. The Company is considering the effect of this FASB issuance, if any, on its financial statements. The Company has decided not to early adopt at this time.

BALANCE_SHEET_DETAILS_Tables

BALANCE SHEET DETAILS (Tables)	12 Months Ended
BALANCE SHEET DETAILS (Tables)	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	Prepaid expenses and other current assets:	As of December 31,
		2014		2013
	Prepaid expenses	$	55	$	92
	Short-term deposits		97		—
	Other		46		14
	Total	$	198	$	106

Property, Plant and Equipment [Table Text Block]	Property and equipment:	As of December 31,
		2014		2013
	Furniture	$	30	$	—
	Computer equipment, software, and other equipment		146		—
	Leasehold improvements		4		—
	Total property and equipment		180		—
	Accumulated depreciation		-35		—
	Total, net	$	145	$	—

Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses:	As of December 31,
		2014		2013
	Accrued compensation and related benefits	$	58	$	266
	Dividends on Series D and E convertible preferred stock		91		26
	Total	$	149	$	292

Schedule of Related Party Transactions [Table Text Block]	Related party liabilities:	As of December 31,
		2014		2013
	Promissory note, 2% interest	$	222	$	222
	Accrued interest		30		26
	Total	$	252	$	248

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Dec. 31, 2014
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The Company had no financial assets or liabilities measured at fair value on a recurring basis at December 31, 2014. Financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013, by level within the fair value hierarchy, are as follows:

		Level 1			Level 2		Level 3		Total
	Derivative liability		—			—		5,859		5,859

	Total fair value	$	—		$	—	$	5,859	$	5,859

Summary of Changes in the Fair value of the Companys Level 3 Financial Liability [Table Text Block]	The following table summarizes the changes in the fair value of the Company’s Level 3 financial liabilities from January 1, 2013 to December 31, 2014:

		Warrant			Derivative
		Liability			Liability		Total
	1-Jan-13	$	233		$	27	$	260
	Issuance of convertible notes		—			8,582		8,582
	Reclass to additional paid in capital		—			-2,712		-2,712
	Change in fair value		-233			-38		-271
	31-Dec-13		—			5,859		5,859
	Conversion of 8% senior convertible debentures to common stock		—			-5,542		-5,542
	Change in fair value		—			-317		-317
	31-Dec-14	$	—		$	—	$	—

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The fair values of the derivative liability measured at each reporting date and at conversion during 2014, and at December 31, 2013, were determined using the Black-Scholes model with the following assumptions:

		2014		2013
	Annualized volatility	78% - 138%		316% - 368%
	Contractual life (years)	0.08 – 0.67		0.03 - 0.93
	Expected dividends	0%		0%
	Risk-free investment rate	0.02% - 0.90%		0.01 - 0.12%

Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The fair value of the warrants at December 31, 2013 was determined using the Black-Scholes model with the following assumptions:

		2013
	Annualized volatility	331% - 335%
	Contractual life (years)	0.04
	Expected dividends	0%
	Risk-free investment rate	0.62 - 0.91%

NET_LOSS_PER_SHARE_Tables

NET LOSS PER SHARE (Tables)	12 Months Ended
NET LOSS PER SHARE (Tables)	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the periods indicated:

		Year Ended December 31,
		2014		2013
	Numerator
	Net loss	$	-27,277	$	-15,132
	Preferred stock dividend		875		38
	Net loss applicable to common stockholders	$	-28,152	$	-15,170

	Denominator
	Weighted average shares outstanding during the period:
	Common stock - basic		738,950,704		450,931,510
	Common shares equivalents		49,983,274		—
	Common stock - diluted		788,933,978		450,931,510

	Basic and diluted net loss per common share	$	-0.04	$	-0.03

	Potentially dilutive securities consist of:

		As of December 31,
		2014		2013
	Outstanding common stock options		30,196,127		6,941,288
	Outstanding preferred stock options		2,487,500		2,287,500
	Related party liabilities		3,070,663		3,107,356
	Warrants		46,636,722		84,553,306
	Convertible promissory note(s)		—		6,325,000
	8% senior convertible debentures		—		75,000,000
	Convertible preferred stock- Series C		750,000		750,000
	Convertible preferred stock- Series D		43,310,900		43,310,900
	Convertible preferred stock- Series E		56,250,000		—

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
INTANGIBLE ASSETS (Tables)	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	Intangible assets consist of:	As of December 31,
		2014		2013
	Intellectual properties		1,685	$	681
	Accumulated amortization		-188		-70
	Total intangible assets, net	$	1,497	$	611

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Intangible assets are amortized over the expected remaining useful lives. As of December 31, 2014, amortization expense for the next five years is expected to be as follows:

	2015	$	128
	2016		128
	2017		128
	2018		128
	2019		128
	Thereafter		857
	Total	$	1,497

CONVERTIBLE_DEBT_Tables

CONVERTIBLE DEBT (Tables)	12 Months Ended
CONVERTIBLE DEBT (Tables)	Dec. 31, 2014
Convertible Promissory Notes Payable [Member]
Schedule of Debt [Table Text Block]				Stated				Principal Balance Outstanding
				Interest				As of December 31,
	Issue Date	Maturity Date		Rate			Conversion Terms	2014		2013
	6/5/13		12/2/13		6	%	Fixed at $0.02		—	$	20
	11/4/12		5/3/13		6	%	Fixed at $0.01		—		10
	8/23/12		2/19/13		6	%	Fixed at $0.015		—		50
	Nov-12		On Demand		None		Refundable excess payment		—		1
	6/6/11		6/6/13		5	%	Variable at $0.04		—		10
	4/11/11		4/11/13		5	%	Variable at $0.04		—		25
	5/1/11		5/1/13		5	%	Fixed at $0.10		—		4
	4/1/11		4/1/13		5	%	Fixed at $0.10		—		4
	Total convertible promissory notes							$	—	$	124

Senior Convertible Debentures 8 [Member]
Schedule of Debt [Table Text Block]	8% Senior convertible debentures
				Stated				Principal Balance Outstanding
		Maturity		Interest				As of December 31,
	Issue Date	Date		Rate			Conversion Terms	2014		2013
	10/2/13		10/2/14		8	%	Variable conversion price	$	—	$	1,789
	9/6/13		9/6/14		8	%	Variable conversion price		—		1,544
	Total principal								—		3,333
	Discount on convertible promissory notes								—		-2,401
	8% senior convertible debentures, net							$	—	$	932

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future non cancellable minimum lease payments are:

	2015		146
	2016		139
	Total	$	285

PREFERRED_STOCK_Tables

PREFERRED STOCK (Tables)	12 Months Ended
PREFERRED STOCK (Tables)	Dec. 31, 2014
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions1 [Table Text Block]	The fair value was determined to be using the Black-Scholes model with the following assumptions which the Company believes approximates the fair value under a binomial lattice model:

	Annualized volatility ⁽¹⁾	305	%
	Contractual term	5
	Risk-free investment rate	1.65	%
	Dividend yield	0	%

Warrant [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes the Company’s warrant activity for the years ended December 31, 2013 and December 31, 2014:

				Weighted		Weighted Average
			Number of	Average		Remaining
			Warrants	Exercise Price		Contractual Term
	Outstanding as of December 31, 2012		12,584,829	$	0.04	4.74
	Issued in connection with convertible debt offerings		83,333,250		0.06
	Exercised		—		—
	Cancelled		-11,364,773		0.04
	Outstanding as of December 31, 2013		84,553,306	$	0.06	2.69
	Issued in connection with warrant exchange		45,000,000		0.12
	Exercised		-82,916,584		0.06
	Outstanding (exercisable) as of December 31, 2014		46,636,722	$	0.12	4.06

COMMON_STOCK_Tables

COMMON STOCK (Tables)	12 Months Ended
COMMON STOCK (Tables)	Dec. 31, 2014
Equity [Abstract]
Schedule Of Available Amounts Under Financing Agreements [Table Text Block]	Issuances through December 31, 2014 and the remaining available amounts under the financing agreement:

		Commitment				Financing
		Fee Shares		Shares Sold		Available
	Total under agreement		9,500,000			$	20,000
	Issued at execution		-6,000,000		4,000,000
	Issued subsequent to execution		-468,001		26,041,120		-2,674
	Total activity		-6,468,001		30,041,120		-2,674
	Available for issue at December 31, 2014		3,031,999			$	17,326

STOCK_OPTION_PLANS_Tables

STOCK OPTION PLANS (Tables)	12 Months Ended
STOCK OPTION PLANS (Tables)	Dec. 31, 2014
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense for all plans for the years ended December 31, 2014and 2013 is classified in the statements of operations as follows:

			Year Ended December 31,
			2014			2013
	Research and development		$	412		$	338
	General and administrative			890			406
	Total		$	1,302		$	744

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the Company’s stock-based awards during the twelve months ended December 31, 2014 and 2013 were estimated using the following assumptions:

		Year Ended December 31,
				2014			2013
	Weighted-average volatility			288	%		90	%
	Weighted-average expected term			5.8			5
	Expected dividends			0	%		0	%
	Risk-free investment rate			2	%		2	%
	Expected forfeiture rate			0	%		0	%

Stock Plan 2008 [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table is a summary of activity under the 2008 Plan:

									Weighted
			Common						Average		Aggregate
			stock						Remaining		Intrinsic
			options						Contractual		Value
			outstanding				Weighted Average Exercise Price ($)		Term (years)		$0
	Balance – December 31, 2012			1,829,026		$	0.02			6.4
	Options granted (weighted-average fair value of $0.52)
	Employee			776,924			0.05			9.2
	Non-employee			5,746,155			0.05			9.2
	Options cancelled			-1,210,817			0.01			—
	Options exercised			-200,000			0.05			—
	Balance December 31, 2013			6,941,288			0.05			9	$	0
	Options granted (weighted-average fair value of $0.08)
	Employee (1)			12,500,000			0.09			9.3
	Non-employee			3,301,323			0.08			9.3
	Options cancelled			-1,146,484			0.07			—
	Options exercised			—			—			—
	Balance December 31, 2014			21,596,127		$	0.08			8.8	$	47

	Options vested December 31, 2014			16,303,994

		-1	Includes 4,000,000 shares granted to Robert Farrell, the Company’s Chief Financial Officer, 2,000,000 of which are performance-based and vest upon continued service and achievement of a specific goal; and 2,000,000 of which are market-based and vest upon continued service and the Company’s achievement of certain stock price targets. All of these shares have an exercise price of $0.08.

Stock Plan 2014 [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table is a summary of activity under the 2014 Plan:

			Common		Weighted Average		Weighted
			Stock		Exercise Price ($)		Average
			options				Remaining
			outstanding				Contractual
							Term (years)
	Balance – December 31, 2013		—		—		—
	Options granted (weighted-average fair value of $0.09)
	Employee		8,600,000		0.09		9.8
	Non-Employee		—		—		—
	Options cancelled		—		—		—
	Options Exercised		—		—		—
	Balance December 31, 2014		8,600,000		0.09		9.8

	Options vested as of December 31, 2014		716,016

Preferred Stock Plan 2012 [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table is a summary of activity under the Preferred Stock Plan:

									Weighted
			Preferred						Average
			Stock						Remaining
			Options			Weighted Average			Contractual
			Outstanding			Exercise Price ($)			Term (years)
	Balance – December 31, 2012			2,448,000			0.46			9.6
	Preferred options granted (weighted-average fair value of $0.0237)
	Employee			—			—			—
	Non-employee			—			—			—
	Preferred options cancelled			-160,500			0.23			—
	Balance – December 31, 2013			2,287,500			0.47			8.5
	Preferred options granted (weighted-average fair value of $1.61)
	Employee			200,000			2.21			9.3
	Non-employee			—			—			—
	Preferred options cancelled			—			—			—
	Balance – December 31, 2014			2,487,500		$	0.61			8.1

	Preferred options vested at December 31, 2014			1,986,068

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The reported amount of income tax expense attributable to operations for the year differs from the amount that would result from applying domestic federal statutory tax rates to loss before income taxes from operations as summarized below:

		Year ended December 31,
	Loss before income taxes	2014			2013
	United States	$	-27,278		$	-15,132
	Foreign		—			—
	Total Income (Loss) before income taxes	$	-27,278		$	-15,132

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Income tax expense (benefit) for the years ended December 31, 2014 and 2013 differed from the amounts computed by applying the statutory federal income tax rate of 34% to pretax income (loss) as a result of the following:

		Year ended December 31,
		2014			2013
	Federal tax expense (benefit) at statutory rate	$	-9,274		$	-5,145
	State tax expense (benefit), net of federal tax effect		-1,334			-539
	R&D credit		-269			-46
	Non-deductible expenses		1,696			2,192
	Change in valuation allowance		9,181			3,538
	Total tax expense	$	—		$	—

		Year ended December 31,
		2014				2013
	Federal tax expense (benefit) at statutory rate		-34	%			-34	%
	State tax expense (benefit), net of federal tax effect		-4.9	%			-3.6	%
	R&D credit		-1	%			-0.3	%
	Non-deductible expenses		6.2	%			14.5	%
	Change in valuation allowance		33.7	%			23.4	%
	Total tax expense		—	%			—	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The significant components of deferred tax assets are as follows:

		As of December 31,
		2014			2013
	Net operating loss carry-forward	$	12,835		$	7,320
	Tax credit carry-forward		504			204
	Accrued liabilities		1,257			723
	Capitalized start-up costs		15			15
	Depreciation and amortization		2,833			1
	Gross deferred tax assets		17,444			8,263
	Valuation allowance		-17,444			-8,263
	Net deferred tax assets	$	—		$	—

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	It is the Company’s policy to include penalties and interest expense related to income taxes as a component of tax expense, as necessary.

	A summary of unrecognized tax benefits is as follows:

	Ending balance at December 31, 2012	$	17
	Increase (decrease) of unrecognized tax benefits taken in prior years		—
	Increase (decrease) of unrecognized tax benefits related to current year		10
	Increase (decrease) of unrecognized tax benefits related to settlements		—
	Reductions to unrecognized tax benefits related lapsing statute of limitations		—

	Ending balance at December 31, 2013	$	27
	Increase (decrease) of unrecognized tax benefits taken in prior years		—
	Increase (decrease) of unrecognized tax benefits related to current year		35
	Increase (decrease) of unrecognized tax benefits related to settlements		—
	Reductions to unrecognized tax benefits related lapsing statute of limitations		—

	Ending balance at December 31, 2014	$	62

LIQUIDITY_AND_GOING_CONCERN_De

LIQUIDITY AND GOING CONCERN (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Liquidity And Going Concern [Line Items]
Cash and cash equivalents	$214	$1,033	$157

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details)	Dec. 31, 2014
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Details Textual)	12 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details Textual)	Dec. 31, 2014
Minimum [Member]
SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Finite-Lived Intangible Asset, Useful Life	9 years 6 months
Maximum [Member]
SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Finite-Lived Intangible Asset, Useful Life	18 years 6 months

BALANCE_SHEET_DETAILS_Details

BALANCE SHEET DETAILS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Balance Sheet Details [Line Items]
Prepaid expenses and other current assets	$198	$106
Prepaid expenses
Balance Sheet Details [Line Items]
Prepaid expenses and other current assets	55	92
Short-term deposits
Balance Sheet Details [Line Items]
Prepaid expenses and other current assets	97	0
Other
Balance Sheet Details [Line Items]
Prepaid expenses and other current assets	$46	$14

BALANCE_SHEET_DETAILS_Details_

BALANCE SHEET DETAILS (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$180	$0
Accumulated depreciation	-35	0
Property, Plant and Equipment, Net	145	0
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	30	0
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	146	0
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$4	$0

BALANCE_SHEET_DETAILS_Details_1

BALANCE SHEET DETAILS (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Balance Sheet Details [Line Items]
Total	$149	$292
Accrued compensation and related benefits
Balance Sheet Details [Line Items]
Total	58	266
Dividends on Series D and E convertible preferred stock
Balance Sheet Details [Line Items]
Total	$91	$26

BALANCE_SHEET_DETAILS_Details_2

BALANCE SHEET DETAILS (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Balance Sheet Details [Line Items]
Total	$252	$248
Promissory note, 2% interest
Balance Sheet Details [Line Items]
Total	222	222
Accrued interest
Balance Sheet Details [Line Items]
Total	$30	$26

BALANCE_SHEET_DETAILS_Details_3

BALANCE SHEET DETAILS (Details Textual) (USD $)	12 Months Ended
BALANCE SHEET DETAILS (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Balance Sheet Details [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Promissory Notes Payable [Member]
Balance Sheet Details [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.00%
Debt Instrument, Convertible, Conversion Price	$0.08
Debt Conversion, Converted Instrument, Shares Issued	3,071,000

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$0	$5,859
Financial Liabilities Fair Value Disclosure	0	5,859	260
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability		0
Financial Liabilities Fair Value Disclosure		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability		0
Financial Liabilities Fair Value Disclosure		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability		5,859
Financial Liabilities Fair Value Disclosure		$5,859

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$5,859	$260
Issuance of convertible notes		8,582
Conversion of 8% senior convertible debentures to common stock	-5,542
Reclass to additional paid in capital		-2,712
Change in fair value	-317	-271
Balance	0	5,859
Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	0	233
Issuance of convertible notes		0
Conversion of 8% senior convertible debentures to common stock	0
Reclass to additional paid in capital		0
Change in fair value	0	-233
Balance	0	0
Derivative Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	5,859	27
Issuance of convertible notes		8,582
Conversion of 8% senior convertible debentures to common stock	-5,542
Reclass to additional paid in capital		-2,712
Change in fair value	-317	-38
Balance	$0	$5,859

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details 2) (Warrant Liabilities [Member])	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Contractual term	14 days
Dividend Yield	0.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Annualized volatility	331.00%
Risk-free investment rate	0.62%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Annualized volatility	335.00%
Risk-free investment rate	0.91%

FAIR_VALUE_MEASUREMENTS_Detail3

FAIR VALUE MEASUREMENTS (Details 3) (Derivative Liabilities [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividends	0.00%	0.00%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Annualized volatility	138.00%	368.00%
Contractual Life	8 months 1 day	11 months 5 days
Expected dividends	0.02%
Risk-free investment rate	0.02%	0.01%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Annualized volatility	78.00%	316.00%
Contractual Life	29 days	11 days
Risk-free investment rate	0.90%	0.12%

FAIR_VALUE_MEASUREMENTS_Detail4

FAIR VALUE MEASUREMENTS (Details Textual)	12 Months Ended
FAIR VALUE MEASUREMENTS (Details Textual)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Conversion, Converted Instrument, Rate	8.00%
8% Senior Convertible Debentures [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Conversion, Converted Instrument, Rate	8.00%	8.00%

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Numerator
Net loss	($27,277)	($15,132)
Preferred stock dividend	875	38
Net loss applicable to common stockholders	($28,152)	($15,170)
Denominator
Common stock - basic (in shares)	738,950,704	450,931,510
Common shares equivalents (in shares)	49,983,274	0
Common stock - diluted (in shares)	788,933,978	450,931,510
Basic and diluted net loss per common share (in dollars per share)	($0.04)	($0.03)
Potentially dilutive securities:
Outstanding common stock options	30,196,127	6,941,288
Outstanding preferred stock options	2,487,500	2,287,500
Related party liabilities	3,070,663	3,107,356
Warrants	46,636,722	84,553,306
Convertible promissory note(s)	0	6,325,000
8% Senior Convertible Debentures [Member]
Potentially dilutive securities:
Convertible promissory note(s)	0	75,000,000
Series C Preferred Stock [Member]
Potentially dilutive securities:
Convertible preferred stock	750,000	750,000
Series D Preferred Stock [Member]
Potentially dilutive securities:
Convertible preferred stock	43,310,900	43,310,900
Series E Preferred Stock [Member]
Potentially dilutive securities:
Convertible preferred stock	56,250,000	0

NET_LOSS_PER_SHARE_Details_Tex

NET LOSS PER SHARE (Details Textual)	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Intangible assets consist of:
Intellectual properties	$1,685	$681
Accumulated amortization	-188	-70
Total intangible assets, net	$1,497	$611

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
2015	$128
2016	128
2017	128
2018	128
2019	128
Thereafter	857
Total	$1,497	$611

CONVERTIBLE_DEBT_Details

CONVERTIBLE DEBT (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Long-term Debt, Gross	$0	$3,333
Total convertible promissory notes	0	124
Convertible Promissory Notes Payable Issuance One [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	5-Jun-13
Debt Instrument, Maturity Date	2-Dec-13
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Fixed at $0.02
Long-term Debt, Gross	0	20
Convertible Promissory Notes Payable Issuance Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	4-Nov-12
Debt Instrument, Maturity Date	3-May-13
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Fixed at $0.01
Long-term Debt, Gross	0	10
Convertible Promissory Notes Payable Issuance Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	23-Aug-12
Debt Instrument, Maturity Date	19-Feb-13
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Fixed at $0.015
Long-term Debt, Gross	0	50
Convertible Promissory Notes Payable Issuance Four [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	30-Nov-12
Debt Instrument Maturity	On Demand
Debt Instrument, Convertible, Terms of Conversion Feature	Refundable excess payment
Long-term Debt, Gross	0	1
Convertible Promissory Notes Payable Issuance Five [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	6-Jun-11
Debt Instrument, Maturity Date	6-Jun-13
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Variable at $0.04
Long-term Debt, Gross	0	10
Convertible Promissory Notes Payable Issuance Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	11-Apr-11
Debt Instrument, Maturity Date	11-Apr-13
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Variable at $0.04
Long-term Debt, Gross	0	25
Convertible Promissory Notes Payable Issuance Seven [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	1-May-11
Debt Instrument, Maturity Date	1-May-13
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Fixed at $0.10
Long-term Debt, Gross	0	4
Convertible Promissory Notes Payable Issuance Eight [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	1-Apr-11
Debt Instrument, Maturity Date	1-Apr-13
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Fixed at $0.10
Long-term Debt, Gross	$0	$4

CONVERTIBLE_DEBT_Details_1

CONVERTIBLE DEBT (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument, Redemption [Line Items]
Stated Interest Rate	8.00%	8.00%
Long-term Debt, Gross	$0	$3,333
Current portion of 8% convertible promissory notes, net of debt discount	0	932
8% Senior Convertible Debenture Issuance One [Member]
Debt Instrument, Redemption [Line Items]
Issue Date	2-Oct-13
Maturity Date	2-Oct-14
Stated Interest Rate	8.00%
Conversion Terms	Variable conversion price
Long-term Debt, Gross	0	1,789
8% Senior Convertible Debenture Issuance Two [Member]
Debt Instrument, Redemption [Line Items]
Issue Date	6-Sep-13
Maturity Date	6-Sep-14
Stated Interest Rate	8.00%
Conversion Terms	Variable conversion price
Long-term Debt, Gross	0	1,544
8% Senior Convertible Debenture Issuance One And Two [Member]
Debt Instrument, Redemption [Line Items]
Discount	$0	($2,401)

CONVERTIBLE_DEBT_Details_Textu

CONVERTIBLE DEBT (Details Textual) (USD $)	12 Months Ended		1 Months Ended	12 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2013	Dec. 31, 2012	Jul. 31, 2013	Feb. 28, 2013	Aug. 19, 2013
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Rate	8.00%
Convertible Promissory Notes Payable Current	$0	$124
Debt Conversion, Converted Instrument, Amount	130	2,712
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Gains (Losses) on Extinguishment of Debt	-1,250	0
Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			94,130,499
Debt Conversion, Converted Instrument, Amount	7,091	0
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount	115
Debt Conversion Accrued Interest Amount	14
Debt Conversion, Converted Instrument, Shares Issued	6,938,000
Repayment of borrowings	9
Payment Of Accrued Interest Notes Payable	1
Dominion Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			0.1
Proceeds from Convertible Debt				600
Debt Instrument, Interest Rate, Stated Percentage			10.00%
Senior Convertible Debentures 8 [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Rate	8.00%	8.00%
Debt Conversion, Converted Instrument, Principal Amount	3,333
Debt Conversion, Converted Instrument, Accrued Interest Amount	125
Debt Discount Written Off, Convertible Promissory Notes	582
Senior Convertible Debentures 8 [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	86,473,000
Restructuring Of Convertible Debentures and Related Warrants [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					12,500,000
Convertible Promissory Notes Payable Current						375
Debt Instrument, Debt Default, Amount						375
Cashless Warrants Amount						500
Warrants Retired Amount						38
Floorless Discount Percentage						66.60%
Debt Instrument Convertible Conversion Price Two						$0.02
Debt Conversion Convertible Instrument Shares Issuable Two						25,000,000
Debt Conversion Convertible Instrument Amount Three						188
Debt Instrument Convertible Conversion Price Three						$0.02
Debt Conversion, Converted Instrument, Amount						188
Restructuring Of Convertible Debentures and Related Warrants [Member] \| Dominion Capital, LLC. [Member]
Debt Instrument [Line Items]
Convertible Promissory Notes Payable Current						187
Payments Made to Acquire Promissory Notes						563
Debt Conversion Convertible Instrument Amount Two						375
Series D Convertible Preferred Stock
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Maximum \| Dominion Note [Member]
Debt Instrument [Line Items]
Convertible Promissory Notes Payable Current			2,000
Extended Amortization Schedule Payments Provided Amount			250
Minimum \| Dominion Note [Member]
Debt Instrument [Line Items]
Convertible Promissory Notes Payable Current			600
Extended Amortization Schedule Payments Provided Amount			200

DEMAND_PROMISSORY_NOTE_Details

DEMAND PROMISSORY NOTE (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Feb. 14, 2014	Sep. 12, 2014	Aug. 14, 2014	Mar. 12, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Feb. 14, 2014	Sep. 12, 2014	Aug. 14, 2014	Mar. 12, 2014
Demand Promissory Notes [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Dominion Capital, LLC. [Member] \| Notes Payable, Other Payables [Member]
Demand Promissory Notes [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Debt Instrument, Face Amount			$500
Dominion Capital, LLC. [Member] \| Notes Payable, Other Payables [Member] \| Common Stock [Member]
Demand Promissory Notes [Line Items]
Payments To Be Made Extend Debt Maturity Date				10	10
Dominion Capital, LLC. [Member] \| Notes Payable, Other Payables [Member] \| Cash [Member]
Demand Promissory Notes [Line Items]
Payments To Be Made Extend Debt Maturity Date						$10

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Operating Leases Future Minimum Payments [Line Items]
2015	$146
2016	139
Total	$285

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	1 Months Ended	12 Months Ended		1 Months Ended		3 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2014	Jan. 31, 2014	Mar. 31, 2014	Mar. 02, 2015	Feb. 28, 2015	Oct. 31, 2010	Jan. 08, 2015
Loss Contingencies [Line Items]
Operating Leases, Rent Expense	$12	$150	$30
Operating Leases, Future Minimum Payments Due, Total	285	285
Other Expenses		9
Clinical Trial Material [Member]
Loss Contingencies [Line Items]
Payments to Acquire Machinery and Equipment		500
Royalty Agreements [Member]
Loss Contingencies [Line Items]
Royalty Percentage									2.50%
Royalty Agreements [Member] \| Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Royalty Percentage									1.25%
MDx Purchase Agreement [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, Acquisitions				6,500,000
PGI License Agreement [Member]
Loss Contingencies [Line Items]
Payment Of License Agreement Milestone Development Cost					4,000
Payment of License Agreement Milestone Development Cost upon Completion					1,000
Payment of License Agreement Milestone Development Cost upon Submission of Drug Application					3,000
Operating Leases, Future Minimum Payments Due, Total	450	450
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	150	150
PGI License Agreement [Member] \| Intellectual Property [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, Acquisitions						4,000,000
Payments to Acquire Intangible Assets		750
Stock Issued During Period, Value, Acquisitions						250
Buck Institute for Research on Aging [Member] \| Research and Development Arrangement [Member]
Loss Contingencies [Line Items]
Contractual Obligation	300	300
Payments to Acquire in Process Research and Development		150
University of Miami [Member] \| Research and Development Arrangement [Member]
Loss Contingencies [Line Items]
Contractual Obligation	155	155
Payments to Acquire in Process Research and Development		52
Lonza Walkerville [Member]
Loss Contingencies [Line Items]
Payment for Option	250	250
Business Combination Consideration Transferred Description		the Company paid $350 to Lonza on March 31, 2015 and will pay the following additional amounts to Lonza until the earlier of such time as the Option is exercised or August 31, 2015: $400 on April 30, 2015 for the option period of April 1, 2015 to April 30, 2015, $600 on May 31, 2015 for the option period of May 1, 2015 to May 31, 2015, $600 on June 30, 2015 for the option period of June 1, 2015 to June 30, 2015 and $600 on July 31, 2015 for the option period of July 1, 2015 to July 31 2015
Option Agreement Break Up Fee		1,000
Percentage of Net Sales to be Paid as per Share Purchase Agreement		2.00%
Lonza Walkerville [Member] \| Milestone 1 [Member]
Loss Contingencies [Line Items]
Business Combination, Contingent Consideration, Liability	4,000	4,000
Lonza Walkerville [Member] \| Milestone 2 [Member]
Loss Contingencies [Line Items]
Business Combination, Contingent Consideration, Liability	1,000	1,000
Lonza Walkerville [Member] \| Milestone 3 [Member]
Loss Contingencies [Line Items]
Business Combination, Contingent Consideration, Liability	4,000	4,000
Lonza Walkerville [Member] \| Subsequent Event [Member]
Loss Contingencies [Line Items]
Payment for Option										400
Business Combination, Consideration Transferred							300
Lonza Walkerville [Member] \| First Amendment Agreement [Member] \| Subsequent Event [Member]
Loss Contingencies [Line Items]
Business Combination, Consideration Transferred								400
Regenecin [Member] \| Asset Purchase Agreement [Member]
Loss Contingencies [Line Items]
Royalty Percentage	5.00%	5.00%
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued		37,500,000
Option Term		5 years
Exercise Cost Of Option Provided	10,000	10,000
Remaining Payments Paid								2,500
Other Significant Noncash Transaction, Value of Consideration Received		3,600
Stock Issued During Period, Value, New Issues		3,000
Payments of Stock Issuance Costs		1,100
Excess Of Gross Revenues		150,000
The Washington Universit [Member] \| Research and Development Arrangement [Member]
Loss Contingencies [Line Items]
Contractual Obligation	120	120
Payments to Acquire in Process Research and Development		$60

PREFERRED_STOCK_Details

PREFERRED STOCK (Details) (Warrant [Member], USD $)	12 Months Ended
PREFERRED STOCK (Details) (Warrant [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option Outstanding - Beginning Balance	84,553,306	12,584,829
Number of Shares - Issued in connection with convertible debt offerings	45,000,000	83,333,250
Preferred Stock Option Outstanding - Options Exercised	-82,916,584	0
Preferred Stock Option Outstanding - Options Cancelled		-11,364,773
Option Outstanding - Ending Balance	46,636,722	84,553,306	12,584,829
Weighted Average Exercise Price - Beginning Balance	$0.06	$0.04
Weighted Average Exercise Price - Issued in connection with convertible debt offerings	$0.12	$0.06
Weighted Average Exercise Price - Exercised	$0.06	$0
Weighted Average Exercise Price - Options cancelled		$0.04
Weighted Average Exercise Price - Ending Balance	$0.12	$0.06	$0.04
Weighted Average Remaining Contractual Term-Balance	4 years 22 days	2 years 8 months 8 days	4 years 8 months 26 days

PREFERRED_STOCK_Details_1

PREFERRED STOCK (Details 1) (Warrant Exchange [Member])	12 Months Ended
PREFERRED STOCK (Details 1) (Warrant Exchange [Member])	Dec. 31, 2014
Warrant Exchange [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Annualized volatility	305.00%
Contractual term	5 years
Risk-free investment rate	1.65%
Dividend Yield	0.00%

PREFERRED_STOCK_Details_Textua

PREFERRED STOCK (Details Textual) (USD $)	12 Months Ended		0 Months Ended	1 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Mar. 07, 2014	31-May-12	Apr. 30, 2013	Aug. 19, 2013	Nov. 07, 2014	Apr. 02, 2015
Preferred Stock, Par Value						$1,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Adjustments to Additional Paid in Capital, Warrant Issued		$1,939
Gain Loss On Issuance Of Warrant	-3,867	0
Preferred Stock Shares Convertible Conversion Price								$0.08
Subsequent Event [Member]
Preferred Stock Shares Convertible Conversion Price								$0.05
Subsequent Event [Member] \| Original Warrants [Member]
Warrants To Purchase Of Common Stock Price Per Share			$0.06
Adjustments to Additional Paid in Capital, Warrant Issued			60,000,000
Proceeds from Warrant Exercises			45,000,000
Subsequent Event [Member] \| New Warrants [Member]
Common Stock Warrants Closing Price Per Share			$0.18
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.12
Debenture And Warrant Transaction [Member]
Warrants Exercise Price Per Share	$0.06
Warrants Exercise Price Per Share Based On Conditions	$0.00
Series A Convertible Preferred Stock [Member]
Preferred Stock Shareholders Entitled To Receive Stated Value Per Share				$1
Preferred Stock Shares, Designated	250,000	250,000
Convertible Preferred Stock Shares Converted To Common Stock				8,094,117
Conversion of Stock, Description	The series A shares are convertible into the Companys common stock at a stated conversion price that is equal to the lessor of 1) 110% of the closing common stock price on the date of conversion or 2) 80% of the lowest closing common stock price occurring during a 30 trading day period prior to notice of conversion.
Preferred Stock, Par Value	$0.00	$0.00
Series B Convertible Preferred Stock [Member]
Preferred Stock Shares, Designated	3,000,000	3,000,000
Preferred Stock, Par Value	$0.00	$0.00
Series C Convertible Preferred Stock [Member]
Preferred Stock Shares, Designated	750,000	750,000
Common Stock, Voting Rights					The holders of Series C shares are entitled to 300 common stock equivalent votes per share on all corporate matters except those that by law only require a single series vote
Preferred Stock, Par Value	$0.00	$0.00
Series D Convertible Preferred Stock [Member]
Preferred Stock Shares, Designated	1,300					1,300
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments						1,250
Preferred Stock, Conversion Basis						The conversion price for the Series D Preferred Stock shall equal $0.03 per share, subject to adjustment under certain conditions. The Series D Preferred Stock is also subject to redemption by the Series D Preferred Stockholders upon certain triggering events. The redemption amount upon any triggering event is equal to the greater of 1) 130% of the stated value or 2) the stated value divided by the then conversion price multiplied by the VMAP on the trading day immediately preceding the triggering event, plus any accrued and unpaid dividends
Preferred Stock, Par Value	$1,000
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Preferred Stock Discount On Shares Percentage	10.00%
Preferred Stock Shares Convertible Conversion Price							$0.03
Preferred Stock Convertible Beneficial Conversion Feature	321
Preferred Stock, Discount on Shares	130
Series E Convertible Preferred Stock [Member]
Preferred Stock Shares, Designated							4,500
Preferred Stock, Par Value							$1,000
Stock Issuance Costs	43
Sale of Stock, Number of Shares Issued in Transaction	3,944
Sale of Stock, Consideration Received on Transaction	3,507
Preferred Stock, Dividend Rate, Percentage							12.00%
Preferred Stock Discount On Shares Percentage	10.00%
Preferred Stock Shares Convertible Conversion Price							$0.08
Preferred Stock Convertible Beneficial Conversion Feature	376
Preferred Stock, Discount on Shares	450
Series E Convertible Preferred Stock [Member] \| Notes Payable, Other Payables [Member]
Debt Instrument Retired Amount	$500
Stock Issued During Period, Shares, Other	556

COMMON_STOCK_Details

COMMON STOCK (Details) (Common Stock [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014
Common Stock [Member]
Common Stock [Line Items]
Commitment Fee Shares under agreement	9,500,000
Commitment Fee Shares Issued at execution	-6,000,000
Commitment Fee Shares Issued Subsequent To Execution	-468,001
Commitment Fee Shares Total activity	6,468,001
Commitment Fee Shares Available for issue at December 31, 2014	3,031,999
Shares Sold Issued at execution	4,000,000
Shares Sold Issued subsequent to execution	26,041,120
Shares Sold Total activity	30,041,120
Financing Available under agreement	$20,000
Financing Available Issued subsequent to execution	-2,674
Financing Available Total activity	-2,674
Financing Available for issue at December 31, 2014	$17,326

COMMON_STOCK_Details_Textual

COMMON STOCK (Details Textual) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Common Stock [Line Items]
Common Stock, Shares Authorized		2,000,000,000	1,000,000
Common Stock, Par or Stated Value Per Share		$0.00	$0.00
LPC Purchase Agreement [Member]
Common Stock [Line Items]
Stock Purchase Agreement Description	the per share purchase price will be the lesser of the lowest sale price of common stock on the purchase date or the average of the three lowest closing purchase prices during the ten consecutive business days prior to the purchase date
Equity Financing Agreement Term	30 months
Percentage of Weighted Average Price Determined Under Equity Financing Agreement	94.00%
Shares Obligated to Purchase Under Equity Financing Agreement		9,500,000
Shares Issuable upon Entering into Equity Financing Agreement		6,000,000
Shares Contingently Issuable Under Equity Financing Agreement		3,500,000
Shares Issued Under Equity Financing Agreement, Shares		4,000,000
Shares Issued Under Equity Financing Agreement, Value		$400
Value Of Shares Obligated to Purchase Under Equity Financing Agreement	20,000
Shares Issuable Upon Entering Into Equity Financing Agreement Treated As Deferred Funding Fee		6,000,000
Value Of Shares Issuable Upon Entering Into Equity Financing Agreement Treated As Deferred Funding Fee		$516

STOCK_OPTION_PLANS_Details

STOCK OPTION PLANS (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
2008 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option Outstanding - Beginning Balance	6,941,288		1,829,026
Preferred Stock Option Outstanding - Options granted Employee	12,500,000	[1]	776,924
Preferred Stock Option Outstanding - Options granted Non-Employee	3,301,323		5,746,155
Common Stock Option Outstanding - Options Cancelled	-1,146,484		-1,210,817
Common Stock Option Outstanding - Options Exercised	0		-200,000
Option Outstanding - Ending Balance	21,596,127		6,941,288	1,829,026
Options vested December 31, 2014	16,303,994
Weighted Average Exercise Price - Beginning Balance	$0.05		$0.02
Weighted Average Exercise Price - Options granted Employee	$0.09	[1]	$0.05
Weighted Average Exercise Price - Options granted Non-Employee	$0.08		$0.05
Weighted Average Exercise Price - Options cancelled	$0.07		$0.01
Weighted Average Exercise Price - Exercised	$0		$0.05
Weighted Average Exercise Price - Ending Balance	$0.08		$0.05	$0.02
Weighted Average Remaining Contractual Term-Balance	8 years 9 months 18 days		9 years	6 years 4 months 24 days
Outstanding Options Common Weighted Average Remaining Contractual Term - Employee	9 years 3 months 18 days	[1]	9 years 2 months 12 days
Weighted Average Remaining Contractual Term - Non-Employee	9 years 3 months 18 days		9 years 2 months 12 days
Aggregate Intrinsic Value - Beginning Balance	$0
Aggregate Intrinsic Value - Ending Balance	$47		$0
2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option Outstanding - Beginning Balance	0
Preferred Stock Option Outstanding - Options granted Employee	8,600,000
Preferred Stock Option Outstanding - Options granted Non-Employee	0
Common Stock Option Outstanding - Options Cancelled	0
Common Stock Option Outstanding - Options Exercised	0
Option Outstanding - Ending Balance	8,600,000
Options vested December 31, 2014	716,016
Weighted Average Exercise Price - Beginning Balance	$0
Weighted Average Exercise Price - Options granted Employee	$0.09
Weighted Average Exercise Price - Options granted Non-Employee	$0
Weighted Average Exercise Price - Options cancelled	$0
Weighted Average Exercise Price - Exercised	$0
Weighted Average Exercise Price - Ending Balance	$0.09
Weighted Average Remaining Contractual Term-Balance	9 years 9 months 18 days
Outstanding Options Common Weighted Average Remaining Contractual Term - Employee	9 years 9 months 18 days

[1]	Includes 4,000,000 shares granted to Robert Farrell, the Companybs Chief Financial Officer, 2,000,000 of which are performance-based and vest upon continued service and achievement of a specific goal; and 2,000,000 of which are market-based and vest upon continued service and the Companybs achievement of certain stock price targets. All of these shares have an exercise price of $0.08.

STOCK_OPTION_PLANS_Details_1

STOCK OPTION PLANS (Details 1) (Preferred Stock Plan 2012 [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Preferred Stock Plan 2012 [Member]
Option Outstanding - Beginning Balance	2,287,500	2,448,000
Preferred Stock Option Outstanding - Options granted Employee	200,000	0
Preferred Stock Option Outstanding - Options granted Non-Employee	0	0
Preferred Stock Option Outstanding - Options Cancelled	0	-160,500
Option Outstanding - Ending Balance	2,487,500	2,287,500	2,448,000
Preferred options vested	1,986,068
Weighted Average Exercise Price - Beginning Balance	$0.47	$0.46
Weighted Average Exercise Price - Options granted Employee	$2.21	$0
Weighted Average Exercise Price - Options granted Non-Employee	$0	$0
Weighted Average Exercise Price - Options cancelled	$0	$0.23
Weighted Average Exercise Price - Ending Balance	$0.61	$0.47	$0.46
Weighted Average Remaining Contractual Term-Balance	8 years 1 month 6 days	8 years 6 months	9 years 7 months 6 days
Weighted Average Remaining Contractual Term - Employee	9 years 3 months 18 days	0 years
Weighted Average Remaining Contractual Term - Non-Employee	0 years	0 years

STOCK_OPTION_PLANS_Details_2

STOCK OPTION PLANS (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$1,302	$744
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	412	338
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$890	$406

STOCK_OPTION_PLANS_Details_3

STOCK OPTION PLANS (Details 3)	12 Months Ended
STOCK OPTION PLANS (Details 3)	Dec. 31, 2014	Dec. 31, 2013
Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Weighted-average volatility	288.00%	90.00%
Weighted-average expected term	5 years 9 months 18 days	5 years
Expected dividends	0.00%	0.00%
Risk-free investment rate	2.00%	2.00%
Expected forfeiture rate	0.00%	0.00%

STOCK_OPTION_PLANS_Details_Tex

STOCK OPTION PLANS (Details Textual) (USD $)	12 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Nov. 30, 2012	Jul. 15, 2012	Jul. 31, 2012	Aug. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$1,510
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 6 months
Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	4,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$0.08
Chief Financial Officer [Member] \| Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,000,000
Chief Financial Officer [Member] \| Market Based Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,000,000
Stock Plan 2008 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	46,119,832
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$0.08	$0.52
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,346,484
Preferred Stock Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,200,000	1,248,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					4 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$1.61	$0.02
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	512,500
Stock Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						153,880,168
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$0.09
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	145,280,168

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule of Income Before Income Tax, Domestic And Foreign [Line Items]
United States	($27,278)	($15,132)
Foreign	0	0
Total Income (Loss) before income taxes	($27,278)	($15,132)

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Components Of Income Tax Expense Benefit [Line Items]
Federal tax expense (benefit) at statutory rate	($9,274)	($5,145)
State tax expense (benefit), net of federal tax effect	-1,334	-539
R&D credit	-269	-46
Non-deductible expenses	1,696	2,192
Change in valuation allowance	9,181	3,538
Total tax expense	$0	$0
Federal tax expense (benefit) at statutory rate	-34.00%	-34.00%
State tax expense (benefit), net of federal tax effect	-4.90%	-3.60%
R&D credit	-1.00%	-0.30%
Non-deductible expenses	6.20%	14.50%
Change in valuation allowance	33.70%	23.40%
Total tax expense	0.00%	0.00%

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Deferred Tax Assets and Liabilities [Line Items]
Net operating loss carry-forward	$12,835	$7,320
Tax credit carry-forward	504	204
Accrued liabilities	1,257	723
Capitalized start-up costs	15	15
Depreciation and amortization	2,833	1
Gross deferred tax assets	17,444	8,263
Valuation allowance	-17,444	-8,263
Net deferred tax assets	$0	$0

INCOME_TAXES_Details_3

INCOME TAXES (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Beginning balance	$27	$17
Increase (decrease) of unrecognized tax benefits taken in prior years
Increase (decrease) of unrecognized tax benefits related to current year	35	10
Increase (decrease) of unrecognized tax benefits related to settlements	0	0
Reductions to unrecognized tax benefits related lapsing statute of limitations	0	0
Ending balance	$62	$27

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$9,181	$3,538
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards	32,226	18,374
Operating Loss Carryforwards Expiration Period	beginning in 2028
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	32,190	18,378
Operating Loss Carryforwards Expiration Period	beginning in 2028	beginning in 2028
Domestic Research And Development Credit Carry-Forwards [Member]
Tax Credit Carryforward, Amount	398	134
Tax Credit Carryforward Expiration Period	beginning in 2029
State And Local Research And Development Credit Carry-Forwards [Member]
Tax Credit Carryforward, Amount	$193	$141
Tax Credit Carryforward Expiration Period	beginning in 2029	beginning in 2029

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Details Textual) (USD $)	12 Months Ended	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Oct. 31, 2013	Dec. 31, 2013
Related Party Transaction [Line Items]
Long-term Debt, Gross	$0		$3,333
Director [Member]
Related Party Transaction [Line Items]
Convertible Promissory Note Converted Amount			66
Convertible Promissory Note Converted Shares	4,990,925
Related Party Debt Transactions [Member]
Related Party Transaction [Line Items]
Related Parties Invested Amount		5
Debenture And Warrants Aggregate Purchase Price		15
Warrants Issued To Purchase Common Stock Shares		138,889
Related Party Debt Transactions [Member] \| 8% Senior Convertible Debentures [Member]
Related Party Transaction [Line Items]
Long-term Debt, Gross		6
Neuro Assets [Member]
Related Party Transaction [Line Items]
Consulting services	660		350
Chief Scientific Officer [Member] \| Chief Executive Officer [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	147,265
Joseph Rubinfeld [Member]
Related Party Transaction [Line Items]
Consulting services	$142		$10

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	12 Months Ended		0 Months Ended	1 Months Ended				0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Apr. 02, 2015	Mar. 30, 2015	Feb. 23, 2015	Mar. 25, 2015	Mar. 11, 2015	Jan. 13, 2015	Jan. 08, 2015	Mar. 04, 2015	Mar. 31, 2015
Subsequent Event [Line Items]
Proceeds from Issuance of Convertible Preferred Stock	$3,550	$0
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Preferred Stock, Shares Authorized			7,779
Preferred Stock Shares Convertible Conversion Price			0.08
Debt Conversion, Converted Instrument, Amount	130	2,712
Dominion Capital LLC \| Restricted Stock [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	1,250,000
Debt Conversion, Converted Instrument, Amount	98
Common Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Issued	6,250,000
Make Whole Shares [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Issued	2,375,624
Subsequent Event [Member]
Subsequent Event [Line Items]
Preferred Stock, Shares Authorized			13,335
Preferred Stock Shares Convertible Conversion Price			0.05
Subsequent Event [Member] \| Dominion Capital LLC
Subsequent Event [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion										500
Subsequent Event [Member] \| Series E Preferred Stock [Member]
Subsequent Event [Line Items]
Sale of Stock, Number of Shares Issued in Transaction				3,278
Proceeds from Issuance of Convertible Preferred Stock				2,950
Preferred Stock, Conversion Basis			The Amendment also provides that simultaneously with the consummation of a Qualified Public Offering (defined in the Amendment as a public offering for gross proceeds of at least $10,000,000 and listing on a national securities exchange) each share of outstanding Series E Preferred Stock, together with any unpaid Dividends shall be converted into shares of Common Stock of the Company subject to adjustments at a conversion price per share of Series E Preferred Stock equal to the lower of $0.05 or 85% of the public offering price of the Qualified Public Offering (Mandatory Conversion Price). In addition, 30% (25% if no warrants are sold to the public in the Qualified Public Offering) of the Stated Amount of the outstanding Preferred Stock together with any Make-Whole Amount shall, at the Companys option, in whole or in part, be paid in cash or in shares of common stock priced at the Mandatory Conversion Price
Subsequent Event [Member] \| February Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount					2,500
Debt Instrument, Interest Rate, Stated Percentage					12.00%
Debt Instrument, Maturity Date					23-Dec-15
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum					24.00%
Debt Instrument, Payment Terms					At any time upon ten (10) days written notice to Dominion Capital, the Company may prepay any portion of the principal amount of the Note and any accrued and unpaid interest at an amount equal to 110% of the then outstanding principal amount of the Note and guaranteed interest, 10% of which may be paid in cash or, at the Companys option, in common stock or a combination thereof.
Subsequent Event [Member] \| Dominion Capital [Member]
Subsequent Event [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion										500
Subsequent Event [Member] \| Dominion Capital [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Issued						8,333,333	9,977,567
Subsequent Event [Member] \| Dominion Capital [Member] \| Series E Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted						250	299
Subsequent Event [Member] \| Dominion Capital [Member] \| February Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount											350
Subsequent Event [Member] \| Existing Series E Preferred Shareholders [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues			30,000,000
Subsequent Event [Member] \| Option Agreement [Member] \| Georgetown University [Member]
Subsequent Event [Line Items]
Option Agreement Option Term								12 months
Payment For Option Fees								75
Subsequent Event [Member] \| Option Agreement [Member] \| Georgetown University [Member] \| License Agreement Terms [Member]
Subsequent Event [Line Items]
Borrowings under Guaranteed Investment Agreements								10,000
Information Technology commercialize Cost								3,000
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross								500
Subsequent Event [Member] \| Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Sale of Stock, Number of Shares Issued in Transaction						37,445,801
Proceeds from Issuance or Sale of Equity						2,767
Stock Issued During Period, Shares, Issued for Services						484,248
Subsequent Event [Member] \| Merger Agreement [Member] \| DioGenix, Inc [Member]
Subsequent Event [Line Items]
Business Acquisition Consideration Potential Cash Payment									2,000
Business Acquisition, Transaction Costs									500
Subsequent Event [Member] \| Merger Agreement [Member] \| Common Stock [Member] \| DioGenix, Inc [Member]
Subsequent Event [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares									99,378,881